BMJ Open Exploring the association between khat use and psychiatric symptoms: a systematic review

Betsy Edwards 💿 , Naomi Atkins

ABSTRACT

To cite: Edwards B, Atkins N. Exploring the association between khat use and psychiatric symptoms: a systematic review. *BMJ Open* 2022;**12**:e061865. doi:10.1136/ bmjopen-2022-061865

Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (http://dx.doi.org/10.1136/ bmjopen-2022-061865).

Received 10 February 2022 Accepted 05 July 2022



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK

Correspondence to

Betsy Edwards; BHE701@student.bham.ac.uk

Objectives Consumption of the drug khat is high across East Africa and the South-Western Arabian Peninsula despite evidence for its adverse psychiatric effects. This systematic review aims to explore cross-sectional research in the field to determine the strength of the association between khat use and psychiatric symptoms Methods Six databases were searched in October 2021-Ovid Medline, Embase, APA PsycINFO, CINAHL, Scopus and Proquest—using the following search terms: "khat" OR "gat" OR "gaad" OR "catha" OR "miraa" OR "mairungi" AND "depression" OR "anxiety" OR "mania" OR "psych*" OR "schiz*" OR "mental" OR "hallucinations" OR "delusions" OR "bipolar". Eligible studies were crosssectional studies of any population or setting comparing the prevalence of psychiatric symptoms in long term or dependent khat users with non-users. The quality of each study was appraised by the Newcastle-Ottawa scale. A meta-analysis was planned using a random effects model to produce an OR with 95% Cls-using the Mantel-Haenszel method—alongside an I² statistic to represent heterogeneity. The quality of this meta-analysis was appraised using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) scoring system.

Results 35 studies were eligible for inclusion (total participants=31 893), spanning 5 countries (Ethiopia, Somalia, Kenya, Saudi Arabia, UK). Meta-analysis suggests that khat use is associated with an 122% increased prevalence of psychiatric symptoms (OR 2.22, 95% Cls 1.76 to 2.79, p<0.00001, GRADE score: 'very low'). **Conclusions** The high heterogeneity of the meta-analysis is likely due to the wide variation between the studies within the evidence base. To perform a more accurate systematic review, further primary studies are needed with standardised measurements of variables, particularly khat consumption.

PROSPERO registration number CRD42020224510.

INTRODUCTION

The stimulant drug khat consists of the buds and leaves of the plant *Catha edulis*, an evergreen shrub highly prevalent in East Africa and the South-Western Arabian Peninsula.¹² Ethiopia is the world's largest exporter of khat, however, its consumption is highest in Yemen where up to 90% of adult males and 50% of adult females chew khat for 3–4hours per

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ Follows all guidelines listed in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 Checklist for systematic reviews.
- ⇒ Searches published and unpublished literature using search terms that include all commonly-used variations of 'khat' from around the world.
- ⇒ Includes both dependent and non-dependent khat use due to poor definitions of khat usage in primary research studies.
- ⇒ Includes both psychiatric symptoms and psychiatric disorders.

day.^{3–5} Within its local regions, khat chewing has been a cultural tradition for many generations and is thought to increase sociability, concentration, energy and spirituality.²⁶⁷

Psychiatric symptoms have been recognised as a consequence of khat use for several decades.⁸ ⁹ Milder psychological consequences related to its use include anxiety, restlessness, insomnia and dysphoric mood, all of which can reduce quality of life.² ^{8–11} More severe psychological harms associated with its use include psychosis and depression, which in some cases have resulted in acts of suicide and homocide.^{8–11} Users most at risk of these sequelae are those abusing larger amounts of khat—some studies have provided evidence for a dose-dependent relationship—and those with pre-existing psychiatric disorders.^{8–10}

The evidence base exploring the association between khat use and psychiatric symptoms—which consists mostly of cross-sectional studies—is currently small and insufficient.¹² Studies often vary in terms of populations and regions studied, measurement of khat use, symptoms explored and quality of methodology. Hence, results can be inconsistent, making it difficult for academics, policymakers and the public to understand the psychiatric risks of khat consumption. This systematic review aims to investigate the strength of the association between khat use and psychiatric symptoms by collating the evidence we have so far, in order to guide further research in the field and to evaluate the need for any potential interventions for khat users, for example, increased education about potential psychiatric side effects.

METHODS

The protocol for this systematic review can be found on Prospero, with registration number CRD42020224510.¹³ Originally, this systematic review had two objectives: to investigate the strength of the association between khat use and psychiatric symptoms, and secondly to investigate the role of trauma within this relationship. Due to the vast amount of literature in the field, the second objective was removed from the protocol to ensure that the findings would be suitable for one single review. It is recommended that a follow-up review should be conducted exploring the role of trauma.

This review followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guide-lines at all times.¹⁴

Patient and public involvement

No members of the public or patients were involved in the design of this systematic review.

Literature search

A literature search was carried out independently by authors BE and NA in October 2021 using the following search terms:

"khat" OR "qat" OR "qaad" OR "catha" OR "miraa" OR "mairungi"

AND

"depression" OR "anxiety" OR "mania" OR "psych*" OR "schiz*" OR "mental" OR "hallucinations" OR "delusions" OR "bipolar"

These search terms encompassed all previously reported psychiatric symptoms associated with khat, and included all predominant cultural variations of the term 'khat' as identified by the Medical Subject Headings Thesaurus.¹⁵ Advice was provided by the library team at the University of Birmingham. Note that studies surrounding suicidality were excluded, as suicidality is often but not always associated with psychiatric dysfunction.¹⁶ Disagreements between the authors were discussed in person. Removal of duplicates was automated for the databases Ovid MEDLINE, Embase and APA PsycINFO, and was performed manually for the remaining databases.

Six electronic databases were searched. Five of these were databases of published literature: Ovid MEDLINE, Embase, APA PsycINFO, CINAHL and Scopus. Additionally, Proquest was searched to obtain any relevant grey or unpublished literature. The full search strategy for each database can be found in online supplemental material 1.

Study eligibility

2

The literature search used the following inclusion criteria:

- ▶ Population: adults (aged 18+).
- Exposure: long-term or dependent khat use.
- Comparator: no khat use or non-dependent khat use*.
- Outcome: prevalence of psychiatric symptoms in khat users and prevalence of psychiatric symptoms in non-users.
- Study design: cross-sectional studies; note that mixedmethod studies are considered eligible but only the cross-sectional data will be considered for the review.
- ► Language: all.
- Publication type: must be a complete study but no restriction on publication status.
- ► Setting: all.
- Date of publication: all.

Each potentially eligible study was compared with a checklist of the above criteria to determine whether or not it should be included within the review.

*Note that non-dependent khat use was only considered a suitable comparator for studies where the exposure group were dependent khat-users, where both dependence and non-dependence were validated by a recognised tool such as the Severity of Dependence Scale.

The literature search used the following exclusion criteria:

- ▶ Population: children, animals.
- Exposure: substance abuse other than khat.
- Comparator: 'substance users' where khat use is not specifically described.
- Outcome: neurobehavioural processes, withdrawal symptoms, suicide, substance use disorders.
- Study design: any study design other than crosssectional, for example, case control, randomised controlled trial, case report, review.
- ► Language: no exclusion criteria.
- Publication type: unfinished studies including abstract only, conference abstracts, letters, retracted articles, book chapters.
- ► Setting: no exclusion criteria.

Data collection and quality assessment

A summary of findings table—see online supplemental material 2—was created to present the following study features: population, sample, criteria for 'khat user', psychiatric measure, effect estimate. In addition, the quality of each primary study (e.g., risk of bias due to inadequate reporting methods or missing data) was assessed using the Newcastle-Ottawa Scale (see online supplemental material 3).^{17 18} Data were collected manually by both authors independently, with any disagreements between the independent assessments resolved by discussion.

Synthesis of findings

The prevalence of khat-users and non-users with psychiatric symptoms from each study was entered into a metaanalysis using the software Revman, provided by the Cochrane organisation. After inputting all dichotomous




Figure 1 PRISMA flow chart of included and excluded studies. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.

values, this software created a forest plot of ORs, each with 95% CIs, using the Mantel-Haenszel method.¹⁹ A random effects model was used as this assumes that the outcome is normally distributed, hence attributing the differences between studies to both chance and genuine variation.¹⁹ An I² statistic was given to indicate variability between studies, as this is again recommended by the Cochrane organisation.²⁰

A subgroup analysis was also included, grouping studies investigating similar symptoms. An OR and I² statistic was provided for each subgroup, as well as a χ^2 test and p value for overall subgroup differences.

A sensitivity analysis was conducted to look for any studies that are prominent outliers. Each study was removed from the meta-analysis one at a time, and the OR, 95% CIs, I^2 value and p value reported within a table.

The quality of the meta-analysis was evaluated using the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) framework.²¹

RESULTS

Included and excluded studies

The PRISMA flow chart in figure 1 shows the number of studies included and excluded at each stage of the literature search.¹⁴ When searching the relevant databases, 1641 results were found that included the relevant terms within their title or abstract. After removing duplicates, this number was reduced to 616.

Each title and abstract were screened, and 567 results were removed for the following reasons:

- One hundred and nineteen were not research studies, for example, these included conference abstracts, letters, and newspaper/magazine articles.
- ► Thirty were animal studies.
- Seventy-one were reviews, including systematic reviews and meta-analyses.
- Twenty were case studies or case reports.
- ► Four were case-control studies or randomised controlled trials.
- Eleven were qualitative studies.
- ► A total of 312 did not explore the relationship between khat use and psychiatric symptoms.

Forty-nine studies were read in full in order to determine their eligibility. Of these, 14 were excluded for the following reasons:

- ▶ Nine explored both khat use and psychiatric symptoms but not their prevalence.²²⁻³⁰
- ► Four did not report khat-use alone, and instead reported substance use or equivalent.³¹⁻³⁴
- One only reported the prevalence of khat use alongside 'three or more psychiatric issues'.¹⁰
 Thirty-five studies were included in the final review.⁷³⁵⁻⁶⁸

Summary of included studies

The summary of findings table—online supplemental material 2—contains the effect estimates of each individual study, alongside each study's characteristics (ie, target population, sample and methods of measuring khat use and psychiatric symptoms).

A subsequent table—online supplemental material 3—provides information regarding the quality of each primary study, assessed using the Newcastle-Ottawa Scale.¹⁷ ¹⁸ According to Mekuriaw *et al*, a score of 5/10 indicates a medium-quality study while a score of 6/10 indicates a high-quality study.⁶⁹ In this systematic review, the average quality score was 6.8, with a range of 4–8. No issues due to missing data arose.

Symptoms explored within included studies

The included studies explored a range of symptoms in association with khat usage. These have been grouped into the following subgroups:

- Twelve studies explored symptoms of 'depression'; this subgroup includes 'depressive symptoms', 'feeling depressed', diagnoses of depression, and the presence of 'depressive episodes' within the last month.
- Six studies explored symptoms of anxiety'; this subgroup includes 'feeling anxious', 'obsessioncompulsion', 'phobic anxiety' and diagnoses of anxiety disorders.
- Sixteen studies explored symptoms of 'psychological distress'; this subgroup includes 'psychological stress', 'psychological distress', 'mental distress' and 'stress'.
- Six studies explored symptoms of psychotic disorders; this subgroup includes 'psychotic symptoms', 'psychosis', 'paranoid ideation', 'psychoticism' and diagnoses of 'schizophrenia'.
- One study explored psychopathy.

- ► Five studies explored unspecified psychiatric symptoms and disorders; this subgroup includes 'common mental disorders', 'psychiatric dysfunction', 'mental illness' and 'mental problems that prevent employment or household tasks'.
- ▶ No studies explored bipolar disorder or mania.

Meta-analysis

The meta-analysis of the 35 included studies can be seen in figure 2. This meta-analysis suggests that khat use is associated with an 122% increased prevalence of psychiatric symptoms (OR 2.22, 95% CIs 1.76 to 2.79, p<0.00001). All but one of the 35 studies were scored as at least medium or high-quality when assessed using the Newcastle-Ottawa Scale; the remaining study scored 4/10—where 5/10 is medium quality—and had a very small weighting within the meta-analysis of 1.5%. The heterogeneity of this meta-analysis is 92%, which is classified as high.^{20 21}

Subgroup analysis

The accompanying subgroup analysis—grouping studies investigating similar symptoms—shows that there is a statistically significant subgroup effect of p=0.04; usually, a p value of less than 0.1 is regarded as a statistically significant subgroup effect.⁷⁰ This means that khat use has a varying association with the symptoms investigated.

The largest association found is between khat use and symptoms of psychological distress (OR 2.56, 95% CIs 1.82 to 3.61, p<0.00001). A higher OR can be found in the psychopathology category (OR 6.10, 95% CIs 2.81 to 13.28), but as this is only composed of one single study this has not been considered as a subgroup.

The two subgroups of symptoms with the lowest ORs are anxiety (OR 1.68, 95% CIs 0.93 to 3.04) and psychotic symptoms/disorders (OR 1.47, 95% CIs 0.93 to 2.30). As the CIs cross the null value in both of these subgroups, this meta-analysis suggests that neither anxiety nor psychotic symptoms are associated with khat use.

Every subgroup has at least five studies to support it, a reasonable amount of supporting evidence. Most of these subgroups have a high level of heterogeneity, apart from the subgroup of unspecified psychiatric symptoms/disorders, which has a heterogeneity of 0%. Note that while psychopathology has been listed as a separate symptom, it is not to be considered as a subgroup as only one study investigated this.

Sensitivity analysis

A sensitivity analysis of the meta-analysis data was conducted and can be seen in online supplemental material 4. Each study was removed in turn and the OR, confidence intervals, I² value and p value recorded. Removing the depression data from Wondemagegn *et al*⁵⁵ caused the largest change in OR, from 2.22 to 2.11. The I² value for heterogeneity remained at 91% or 92% regardless of which study was removed, and the p value was always <0.00001.

GRADE analysis

The meta-analysis shown in figure 2 received a GRADE score of 'very low'.²¹ As per guidance in the GRADE handbook, the score automatically started as 'low', because the meta-analysis focuses on observational studies.²¹ The score was then downgraded for the following two reasons: 'inconsistency of results' demonstrated by the high I^2 statistic, and 'indirectness of evidence' due to the differences between studies including populations investigated and methods of measuring khat use.²¹ The score was not downgraded for publication bias, as despite occasional outliers, overall the funnel plot for the included studies was fairly symmetrical (see figure 3).

DISCUSSION

Our findings suggest that khat use is associated with a 122% increased prevalence in overall psychiatric symptoms (OR 2.22, 95% CIs 1.76 to 2.79, p<0.00001). Subgroup analyses suggest thats suggests that the strongest relationship is between khat use and psychological distress (OR 2.56, 95% CIs 1.82 to 3.61, p<0.00001). Subgroup analyses also found that the associations between khat use and anxiety, and khat use and psychotic symptoms/disorders is statistically insignificant (OR 1.68, 95% CIs 0.93 to 3.04 and OR=1.47, 95% CIs 0.93 to 2.30, respectively).

The overall prevalence of psychiatric symptoms and disorders within this systematic review is 29%. Most of the included studies were conducted in Africa, which the WHO estimates has a 5.5% prevalence of common mental disorders.⁷¹ The prevalence of symptoms is higher in this review than expected, as many of the studies focus on populations with an increased risk of mental illness, for example, students, migrants, combatants, refugees, prisoners and psychiatric outpatients.^{72–76}

This review has a strong, high-quality methodology, following all of the PRISMA guidelines for systematic reviews.¹⁴ However, it can be argued that the evidence base surrounding khat use and psychiatric symptoms is too small to merit the pooling of data. This is reflected in the high heterogeneity of the meta-analysis conducted $(I^2=92\%)$, which suggests that the studies analysed may be too different to meaningfully compare²⁰; these differences are likely to include the wide variety of populations and regions studies, the differences in khat consumption measurement, and the differences in psychiatric symptom explored. It is also reflected in the low GRADE score of the meta-analysis, however, this scoring system favours experimental rather than observational data, which would be both pragmatically and ethically inappropriate when investigating substance use.⁷⁷

Despite these concerns, this review is important as it is currently the largest systematic review of khat usage and psychiatric symptoms. A 122% increase in psychiatric symptoms is easy for laypersons to understand, eliminating their need to evaluate various studies of varying quality against each other. Furthermore, the issues highlighted by this review are important for guiding further research.

1.1 Doproceion	Events	sers Total	Non-us Events		Weight	Odds Ratio M-H, Random, 95% Cl	Odds Ratio M-H, Random, 95% Cl
.1.1 Depression tnafie et al. 2020	41	207	80	271	2.2%	0.59 [0.38, 0.91]	
ledaso et al. 2020	36	48	153	287	2.2%	2.63 [1.31, 5.26]	
)eyessa et al. 2008	71	1199	44	1432	2.2%	1.99 [1.35, 2.92]	
I-Setouhy et al. 2016	13	35	7	32	1.5%	2.11 [0.71, 6.23]	+
laile and Sahile, 2021	67	108	40	276	2.1%	9.64 [5.77, 16.11]	
lambisa et al. January 2020	84	241	190	781	2.2%	1.66 [1.22, 2.27]	-
lelaku et al. 2021	37	56	99	204	2.0%	2.07 [1.11, 3.83]	
lossie et al. 2016	104	200	67	390	2.2%	5.22 [3.56, 7.65]	
luman 2003 Vendemograph et el. 2017	326	538	168	254	2.2%	0.79 [0.58, 1.08]	
Vondemagegn et al. 2017 'eshaw and Mossie, 2017	108 54	172 145	15 27	182 209	2.0% 2.1%	18.79 [10.19, 34.65] 4.00 [2.36, 6.77]	
enebe et al. 2015	58	235	46	130	2.1%	0.60 [0.38, 0.95]	
ubtotal (95% CI)		3184		4448	24.7%	2.39 [1.34, 4.28]	•
otal events	999 8 - 211 24	df = 11	936 /P = 0.0	00043-18	- 05%		
leterogeneity: Tau² = 0.98; Chi 'est for overall effect: Z = 2.93 ((F < 0.0	0001), 1	- 90%		
.1.2 Anxiety							
tnafie et al. 2020	146	207	133	271	2.2%	2.48 [1.69, 3.64]	
il-Setouhy et al. 2016 1elaku et al. 2021	20 41	35 56	10	32	1.6% 2.0%	2.93 [1.08, 8.00]	
luman 2003	203	538	117 141	204 254	2.0%	2.03 [1.06, 3.91] 0.49 [0.36, 0.66]	
luman 2003	410	538	194	254	2.2%	0.99 [0.70, 1.41]	
luman 2003	248	538	135	254	2.2%	0.75 [0.56, 1.02]	
Vondemagegn et al. 2017	79	172	26	182	2.1%	5.10 [3.05, 8.51]	
eshaw and Mossie, 2017	43	145	25	209	2.1%	3.10 [1.79, 5.37]	
ubtotal (95% CI)		2229		1660	16.6%	1.68 [0.93, 3.04]	◆
otal events leterogeneity: Tau ² = 0.66; Chi est for overall effect: 7 = 1.72 /		l, df = 7	781 P < 0.00	001); I² =	93%		
est for overall effect: Z = 1.72 (r = 0.09)						
.1.3 Psychological Distress		4.00			0.00	2 00 // 50 /0	
draro et al. 2019 trafia at al. 2020	119	139	69 67	161	2.0%	7.93 [4.50, 13.99]	
tnafie et al. 2020 elew et al. 1997	33 100	207 326	57 28	271 554	2.1% 2.1%	0.71 [0.44, 1.14] 8 31 (5 32, 13 00]	
elew et al. 1997 achew et al. 2015	100	326	28	722	2.1%	8.31 [5.32, 13.00] 1.96 [1.32, 2.92]	
amena et al. 2013	49	136	108	317	2.2%	1.09 [0.72, 1.66]	<u> </u>
essie et al. 2013	59	185	34	245	2.1%	2.91 [1.80, 4.68]	<u> </u>
ajure et al. 2020	37	57	14	70	1.8%	7.40 [3.33, 16.46]	——
ambisa et al. March 2021	49	59	146	278	1.9%	4.43 [2.16, 9.10]	——
ersi et al. 2017	35	108	78	462	2.1%	2.36 [1.47, 3.78]	
elemu et al. 2020	70	111	145	293	2.1%	1.74 [1.11, 2.73]	
ierebih et al. 2017 Ieleview et al. 2020	18	26	84	264	1.7%	4.82 [2.02, 11.53]	
lekuriaw et al. 2020 Jelaku et al. 2021	39 30	71 56	149 75	647 204	2.1% 2.0%	4.07 [2.47, 6.73]	
ielaku et al. 2021 oboka et al. 2015	30 52	56 93	124	204	2.0%	1.98 [1.09, 3.61] 1.76 [1.10, 2.81]	
	27	72	98	324	2.1%	1.38 [0.81, 2.36]	<u> </u>
oboka et al. 2017	27						
	19	40	71	168	1.9%	1.24 [0.62, 2.47]	
'ariku et al. 2017 'eshaw and Mossie, 2017			71 41	168 209	2.1%	1.24 [0.62, 2.47] 2.81 [1.75, 4.52]	
'ariku et al. 2017 'eshaw and Mossie, 2017 'ubtotal (95% Cl)	19 59	40	41				→
ioboka et al. 2017 iariku et al. 2017 ieshaw and Mossie, 2017 iubtotal (95% CI) iotal events ieteroceneity: Tau [#] = 0.43: Chi	19 59 858	40 145 1945	41 1600	209 5485	2.1% 34.8%	2.81 [1.75, 4.52]	•
'ariku et al. 2017 'eshaw and Mossie, 2017 subtotal (95% CI) 'otal events leterogeneity: Tau² = 0.43; Chi	19 59 858 2 = 116.49	40 145 1945 9, df = 16	41 1600	209 5485	2.1% 34.8%	2.81 [1.75, 4.52]	•
ariku et al. 2017 eshaw and Mossie, 2017 uubtotal (95% CI) otal events leterogeneity: Tau ² = 0.43; Chi iest for overall effect: Z = 5.41 (.1.4 Psychotic Symptoms/Dis	19 59 858 ₹=116.49 (P < 0.000	40 145 1945), df = 16 01)	41 1600 (P < 0.0	209 5485 0001); I ²	2.1% 34.8% = 86%	2.81 [1.75, 4.52] 2.56 [1.82, 3.61]	•
'ariku et al. 2017 'eshaw and Mossie, 2017 'ubitotal (95% CI) 'otal events leterogeneity: Tau ² = 0.43; Chi 'est for overall effect: Z = 5.41 (.1.4 Psychotic Symptoms/Dis luman 2003	19 59 ₽= 116.4§ (P < 0.000) sorders	40 145 1945 9, df = 16	41 1600	209 5485	2.1% 34.8%	2.81 [1.75, 4.52]	•
ariku et al. 2017 eshaw and Mossie, 2017 ubtotal (95% CI) otal events leterogeneity: Tau ² = 0.43; Chi est for overall effect: Z = 5.41 (.1.4 Psychotic Symptoms/Dis luman 2003 uman 2003	19 59 ₽=116.45 (P < 0.000 sorders 228	40 145 1945 9, df = 16 01) 538	41 1600 (P < 0.0 99	209 5485 0001); I ² 254	2.1% 34.8% = 86% 2.2%	2.81 [1.75, 4.52] 2.56 [1.82, 3.61] 1.15 [0.85, 1.56]	•
ariku et al. 2017 eshaw and Mossie, 2017 ubtotal (95% CI) otal events leterogeneity: Tau ² = 0.43; Chi est for overall effect: Z = 5.41 (1.4 Psychotic Symptoms/Dis uman 2003 luman 2003 denwald et al. 2009 ngeri et al. 2019	19 59 ≈ = 116.49 P < 0.000 sorders 228 269	40 145 1945 9, df = 16 01) 538 538	41 1600 (P < 0.0 99 136	209 5485 0001); I ² 254 254	2.1% 34.8% = 86% 2.2% 2.2%	2.81 [1.75, 4.52] 2.56 [1.82, 3.61] 1.15 [0.85, 1.56] 0.87 [0.64, 1.17]	• •
ariku et al. 2017 eshaw and Mossie, 2017 ubtotal (95% CI) otal events leterogeneity: Tau ² = 0.43; Chi est for overall effect: Z = 5.41 (1.4 Psychotic Symptoms/Dis luman 2003 luman 2003 denwald et al. 2009 ingeri et al. 2019 ulloch et al. 2012	19 59 ₽ = 116.4% ₽ < 0.000 sorders 228 269 263 57 28	40 145 1945 9, df = 16 01) 538 538 538 538 538 306 30	41 1600 (P < 0.0 99 136 136 82 2	209 5485 00001); I ² 254 254 254 254 525 30	2.1% 34.8% = 86% 2.2% 2.2% 2.2% 2.2% 0.8%	2.81 [1.75, 4.52] 2.56 [1.82, 3.61] 1.15 [0.85, 1.56] 0.87 [0.64, 1.17] 0.83 [0.62, 1.12] 1.24 [0.85, 1.79] 196.00 [25.77, 1490.50]	• •
ariku et al. 2017 eshaw and Mossie, 2017 ubtotal (95% CI) otal events leterogeneity: Tau ² = 0.43; Chi est for overall effect: Z = 5.41 (.1.4 Psychotic Symptoms/Dis luman 2003 uman 2003 denwald et al. 2009 ngeri et al. 2019 ulloch et al. 2012 /idmann et al. 2014	19 59 ₽ = 116.45 P < 0.000 sorders 263 263 57 28 8 8	40 145 1945 9, df = 16 01) 538 538 538 538 538 306 30 33	41 1600 (P < 0.0 99 136 136 82 2 0	209 5485 00001); I ² 254 254 254 525 30 15	2.1% 34.8% = 86% 2.2% 2.2% 2.2% 0.8% 0.5%	2.81 [1.75, 4.52] 2.56 [1.82, 3.61] 1.15 [0.85, 1.56] 0.87 [0.64, 1.17] 0.83 [0.62, 1.12] 1.24 [0.8, 1.79] 196.00 [27, 71, 490, 50] 10.33 [0.56, 191.82]	• •
ariku et al. 2017 eshaw and Mossie, 2017 ubtotal (95% CI) otal events leterogeneity: Tau ² = 0.43, Chi est for overall effect: Z = 5.41 (1.14 Psychotic Symptoms/Dis uman 2003 uman 2003 uman 2003 uman 2003 udenwald et al. 2009 ungeri et al. 2019 ulloch et al. 2019 ulloch et al. 2014 enebe et al. 2015	19 59 ₽ = 116.4% ₽ < 0.000 sorders 228 269 263 57 28	40 145 1945 9, df = 16 01) 538 538 538 538 538 306 30 33 235	41 1600 (P < 0.0 99 136 136 82 2	209 5485 00001); ² 254 254 254 525 30 15 130	2.1% 34.8% = 86% 2.2% 2.2% 2.2% 0.8% 0.5% 2.1%	2.81 [1.75, 4.52] 2.56 [1.82, 3.61] 0.87 [0.64, 1.17] 0.83 [0.62, 1.12] 1.24 [0.85, 1.79] 196.00 [25.77, 1490.50] 10.33 [0.56, 191.82] 1.88 [1.24, 3.77]	• •
ariku et al. 2017 schaw and Mossie, 2017 ubtotal (95% CI) otal events eterogeneity: Tau ² = 0.43; Chi est for overall effect: Z = 5.41 (1.4 Psychotic Symptoms/Dis uman 2003 uman 2003 uman 2003 denwald et al. 2009 ngeri et al. 2019 ullich et al. 2012 idimann et al. 2014 enebe et al. 2015 ubtotal (95% CI)	19 59 ₽ = 116.4% P < 0.000 sorders 228 269 263 57 28 8 97	40 145 1945 9, df = 16 01) 538 538 538 538 538 306 30 33	41 1600 (P < 0.0 136 136 82 2 0 34	209 5485 00001); I ² 254 254 254 525 30 15	2.1% 34.8% = 86% 2.2% 2.2% 2.2% 0.8% 0.5%	2.81 [1.75, 4.52] 2.56 [1.82, 3.61] 1.15 [0.85, 1.56] 0.87 [0.64, 1.17] 0.83 [0.62, 1.12] 1.24 [0.8, 1.79] 196.00 [27, 71, 490, 50] 10.33 [0.56, 191.82]	
ariku et al. 2017 eshaw and Mossie, 2017 ubtotal (95% CI) otal events leterogeneity: Tau ² = 0.43; Chi est for overall effect Z = 5.41 (.1.4 Psychotic Symptoms/Dis luman 2003 demwald et al. 2009 digeni et al. 2019 ulloch et al. 2019 ulloch et al. 2014 enebe et al. 2014 otal events	19 59 ₽ = 116.45 P < 0.000 sorders 228 263 57 28 8 97 950	40 145 1945 3, df = 16 01) 538 538 538 538 538 306 30 33 235 2218	41 1600 (P < 0.0 99 136 136 82 0 34 489	209 5485 00001); ² 254 254 254 254 525 30 15 130 1462	2.1% 34.8% = 86% 2.2% 2.2% 2.2% 0.8% 0.5% 2.1% 12.3%	2.81 [1.75, 4.52] 2.56 [1.82, 3.61] 0.87 [0.64, 1.17] 0.83 [0.62, 1.12] 1.24 [0.85, 1.79] 196.00 [25.77, 1490.50] 10.33 [0.56, 191.82] 1.88 [1.24, 3.77]	• •
ariku et al. 2017 eshaw and Mossie, 2017 ubtotal (95% CI) otal events leterogeneity: Tau ² = 0.43, Chi est for overall effect: Z = 5.41 (1.4 Psychotic Symptoms/Dis uman 2003 uman 2003 uman 2003 uman 2003 udenwald et al. 2019 ulloch et al. 2019 ulloch et al. 2019 ulloch et al. 2014 enebe et al. 2015 ubtotal (95% CI) otal events	19 59 ₽ = 116.45 P < 0.000 sorders 228 269 263 57 28 8 97 950 ₽ = 40.15,	40 145 1945 3, df = 16 01) 538 538 538 538 538 306 30 33 235 2218	41 1600 (P < 0.0 99 136 136 82 0 34 489	209 5485 00001); ² 254 254 254 254 525 30 15 130 1462	2.1% 34.8% = 86% 2.2% 2.2% 2.2% 0.8% 0.5% 2.1% 12.3%	2.81 [1.75, 4.52] 2.56 [1.82, 3.61] 0.87 [0.64, 1.17] 0.83 [0.62, 1.12] 1.24 [0.85, 1.79] 196.00 [25.77, 1490.50] 10.33 [0.56, 191.82] 1.88 [1.24, 3.77]	• •
ariku et al. 2017 'eshaw and Mossie, 2017 'uibtotal (95% CI) 'otal events leterogeneity: Tau ² = 0.43, Chi est for overall effect. Z = 5.41 (.1.4 Psychotic Symptoms/Dis luman 2003 Uuman 20	19 59 858 8 = 116.4% P < 0.000 sorders 228 269 263 57 28 8 97 950 950 P = 0.10)	40 145 1945 3, df = 16 01) 538 538 538 538 306 30 33 235 2218 df = 6 (F	41 1600 (P < 0.0 99 136 136 82 2 0 34 489 < 0.000	209 5485 0001); * 254 254 254 254 525 300 15 130 1462 01); * =	2.1% 34.8% = 86% 2.2% 2.2% 2.2% 0.8% 0.5% 2.1% 12.3%	2.81 [1.75, 4.52] 2.56 [1.82, 3.61] 1.15 [0.85, 1.56] 0.87 [0.64, 1.17] 0.83 [0.62, 1.12] 1.24 [0.85, 1.79] 196.00 [25.77, 1490.50] 10.33 [0.56, 191.82] 1.98 [1.24, 3.17] 1.47 [0.93, 2.30]	
ariku et al. 2017 eshaw and Mossie, 2017 ubtotal (95% CI) otal events leterogeneity: Tau ² = 0.43; Chi est for overall effect: Z = 5.41 (.1.4 Psychotic Symptoms/Dis luman 2003 luman 2003 uburan 2003 udenwald et al. 2009 ungeri et al. 2019 ulloch et al. 2019 ulloch et al. 2019 ulloch et al. 2019 ulloch et al. 2019 ubtotal (95% CI) otal events leterogeneity: Tau ² = 0.25; Chi est for overall effect: Z = 1.66 (.1.5 Psychopathy Itayih et al. 2020	19 59 ₽ = 116.45 P < 0.000 sorders 228 269 263 57 28 8 97 950 ₽ = 40.15,	40 145 1945 3, df = 16 01) 538 538 538 306 30 33 235 2218 df = 6 (F	41 1600 (P < 0.0 99 136 136 82 0 34 489	209 5485 00001); * 254 254 254 254 255 30 15 130 1462 01); * =	2.1% 34.8% = 86% 2.2% 2.2% 2.2% 2.2% 0.5% 2.1% 12.3% 85%	2.81 [1.75, 4.52] 2.56 [1.82, 3.61] 1.15 [0.85, 1.56] 0.87 [0.64, 1.17] 0.83 [0.62, 1.12] 1.24 [0.85, 1.79] 196.00 [25.77, 1490.50] 10.33 [0.56, 191.82] 1.98 [1.24, 3.17] 1.47 [0.93, 2.30] 6.10 [2.81, 13.28]	
ariku et al. 2017 eshaw and Mossie, 2017 ubtotal (95% CI) otal events leterogeneity: Tau ² = 0.43; Chi est for overall effect: Z = 5.41 (.1.4 Psychotic Symptoms/Dis luman 2003 demwald et al. 2009 ingeri et al. 2019 ulloch et al. 2019 ulloch et al. 2014 enebe et al. 2014 enebe et al. 2014 enebe et al. 2015 ubtotal (95% CI) otal events leterogeneity: Tau ² = 0.25; Chi est for overall effect: Z = 1.66 (.1.5 Psychopathy tayih et al. 2020 ubtotal (95% CI)	19 59 858 F = 116.45 (P < 0.000 sorders 228 269 263 57 28 8 97 97 950 F = 40.15 (P = 0.10) 32	40 145 1945 3, df = 16 01) 538 538 538 538 306 30 33 235 2218 df = 6 (F	41 1600 (P < 0.0 99 136 136 136 82 2 0 34 489 < 0.000 9	209 5485 0001); * 254 254 254 254 525 300 15 130 1462 01); * =	2.1% 34.8% = 86% 2.2% 2.2% 2.2% 0.8% 0.5% 2.1% 12.3%	2.81 [1.75, 4.52] 2.56 [1.82, 3.61] 1.15 [0.85, 1.56] 0.87 [0.64, 1.17] 0.83 [0.62, 1.12] 1.24 [0.85, 1.79] 196.00 [25.77, 1490.50] 10.33 [0.56, 191.82] 1.98 [1.24, 3.17] 1.47 [0.93, 2.30]	
ariku et al. 2017 eshaw and Mossie, 2017 ubtotal (95% CI) otal events leterogeneity: Tau ² = 0.43; Chi est for overall effect: Z = 5.41 (.1.4 Psychotic Symptoms/Dis luman 2003 luman 2003 luman 2003 ubman 2003 ubman 2003 ubman 2003 ubman 2003 ubman 2012 ubloch et al. 2019 ubloch et al. 2019 ubloch et al. 2019 ubloch et al. 2014 enebe et al. 2015 ubtotal (95% CI) otal events leterogeneity: Tau ² = 0.25; Chi est for overall effect: Z = 1.66 (.1.5 Psychopathy itayih et al. 2020 ubtotal (95% CI) otal events leterogeneity: Not applicable	19 59 858 858 80000 800005 228 269 263 263 28 8 97 950 ₹ = 40.15, (P = 0.10) 32 32	40 145 1945 0, df = 10 01) 538 538 538 538 538 306 30 33 235 2218 df = 6 (F 138 138	41 1600 (P < 0.0 99 136 136 82 2 0 34 489 < 0.000	209 5485 00001); * 254 254 254 254 255 30 15 130 1462 01); * =	2.1% 34.8% = 86% 2.2% 2.2% 2.2% 2.2% 0.5% 2.1% 12.3% 85%	2.81 [1.75, 4.52] 2.56 [1.82, 3.61] 1.15 [0.85, 1.56] 0.87 [0.64, 1.17] 0.83 [0.62, 1.12] 1.24 [0.85, 1.79] 196.00 [25.77, 1490.50] 10.33 [0.56, 191.82] 1.98 [1.24, 3.17] 1.47 [0.93, 2.30] 6.10 [2.81, 13.28]	
ariku et al. 2017 eshaw and Mossie, 2017 ubtotal (95% CI) otal events est for overall effect. Z = 5.41 (.1.4 Psychotic Symptoms/Dis luman 2003 luman 2003 ubtotal et al. 2019 ulloch et al. 2019 ulloch et al. 2019 ulloch et al. 2019 ulloch et al. 2014 enebe et al. 2014 enebe et al. 2015 ubtotal (95% CI) otal events leterogeneity. Tota epilcable est for overall effect. Z = 1.66 (.1.5 Psychopathy litayih et al. 2020 ubtotal (95% CI) otal events	19 59 858 858 80000 228 269 263 57 28 8 97 950 7 = 40.15, (P = 0.10) 32 32 (P < 0.000	40 145 1945 0, df = 16 01) 538 538 538 538 538 538 538 538 538 538	41 1600 (P < 0.0 99 136 136 136 82 2 0 34 489 9 9 9 9	209 5485 00001); * 254 254 254 254 255 30 15 130 1462 01); * =	2.1% 34.8% = 86% 2.2% 2.2% 2.2% 2.2% 0.5% 2.1% 12.3% 85%	2.81 [1.75, 4.52] 2.56 [1.82, 3.61] 1.15 [0.85, 1.56] 0.87 [0.64, 1.17] 0.83 [0.62, 1.12] 1.24 [0.85, 1.79] 196.00 [25.77, 1490.50] 10.33 [0.56, 191.82] 1.98 [1.24, 3.17] 1.47 [0.93, 2.30] 6.10 [2.81, 13.28]	
ariku et al. 2017 eshaw and Mossie, 2017 ubtotal (95% CI) otal events leterogeneity: Tau ² = 0.43; Chi est for overall effect: Z = 5.41 (.1.4 Psychotic Symptoms/Dis luman 2003 luman 2003 luman 2003 ubman 2003 ubman 2003 ubman 2003 ubman 2003 ubman 2012 ubloch et al. 2019 ulloch et al. 2019 ulloch et al. 2019 ulloch et al. 2019 ulloch et al. 2014 enebe et al. 2015 ubtotal (95% CI) otal events leterogeneity: Tau ² = 0.25; Chi est for overall effect: Z = 1.66 (.1.5 Psychopathy itayih et al. 2020 ubtotal (95% CI) otal events leterogeneity: Not applicable est for overall effect: Z = 4.56 (.1.6 Unspecified Psychiatric	19 59 858 858 80000 80000 263 269 263 263 8 97 28 8 97 28 8 97 28 8 97 28 8 97 28 28 8 97 28 28 32 32 7 40.15, (P < 0.000 32 32 32 (P < 0.000 80000 263 263 263 263 263 263 263 263 263 263	40 145 1945 3, df = 16 001) 538 538 538 538 538 538 538 538 538 538	41 1600 (P < 0.0 99 136 82 2 2 2 34 489 9 9 9 9 9 9	209 5485 0001); P 254 254 254 254 254 254 254 130 15 130 1462 01); P = 191 191	2.1% 34.8% = 86% 2.2% 2.2% 2.2% 0.5% 2.2% 0.5% 2.1% 12.3% 85%	2.81 [1.75, 4.52] 2.56 [1.82, 3.61] 1.15 [0.85, 1.56] 0.87 [0.64, 1.17] 0.83 [0.62, 1.12] 1.24 [0.85, 1.79] 196.00 [25.77, 1490.50] 10.33 [0.56, 191.82] 1.96 [1.24, 3.17] 1.47 [0.93, 2.30] 6.10 [2.81, 13.28] 6.10 [2.81, 13.28]	
ariku et al. 2017 eshaw and Mossie, 2017 ubtotal (95% CI) otal events leterogeneity: Tau ² = 0.43; Chi est for overall effect: Z = 5.41 (1.4 Psychotic Symptoms/Dis luman 2003 luman 2003 ubtomal det al. 2009 ingeri et al. 2019 ulloch et al. 2019 ulloch et al. 2019 ulloch et al. 2014 enebe et al. 2014 enebe et al. 2015 ubtotal (95% CI) otal events leterogeneity: Tau ² = 0.25; Chi est for overall effect: Z = 1.66 (1.5 Psychopathy itayih et al. 2020 ubtotal (95% CI) otal events leterogeneity: Not applicable est for overall effect: Z = 4.56 (1.6 Unspecified Psychiatric med and Emad 1998	19 59 858 ₽ = 116.45 P < 0.0000 263 263 263 57 28 8 97 28 8 97 28 8 97 28 8 97 28 28 97 28 28 97 28 28 97 28 28 97 28 28 97 28 28 269 263 263 263 263 263 263 263 263 263 263	40 145 1945 3, df = 16 01) 538 538 538 538 538 538 538 538 538 538	41 1600 (P < 0.0 99 136 136 82 2 0 34 489 9 9 9 9 9 9	209 5485 0001); P 254 254 254 254 254 254 255 30 15 30 16 25 10 11; P = 191 191	2.1% 34.8% 2.2% 2.2% 2.2% 0.5% 2.1% 12.3% 35%	2.81 [1.76, 4.52] 2.56 [1.82, 3.61] 1.15 [0.85, 1.56] 0.87 [0.64, 1.17] 0.83 [0.62, 1.12] 1.24 [0.85, 1.73] 196.00 [25, 77, 1490.50] 10.33 [0.56, 191.82] 1.38 [1.24, 3.17] 1.47 [0.93, 2.30] 6.10 [2.81, 13.28] 6.10 [2.81, 13.28]	
ariku et al. 2017 eshaw and Mossie, 2017 ubtotal (95% CI) otal events leterogeneity: Tau ² = 0.43, Chi est for overall effect: Z = 5.41 (.1.4 Psychotic Symptoms/Dis luman 2003 luman 2003 ubtotal et al. 2019 ulloch et al. 2019 ulloch et al. 2019 ulloch et al. 2019 ulloch et al. 2014 enebe et al. 2014 enebe et al. 2015 ubtotal (95% CI) otal events leterogeneity: Tau ² = 0.25; Chi est for overall effect: Z = 1.66 (.1.5 Psychopathy tavih et al. 2020 ubtotal (95% CI) otal events leterogeneity: Not applicable est for overall effect: Z = 4.56 (.1.6 Unspecified Psychiatric med and Emad 1998 edaku 2014	19 59 858 80000 228 269 263 57 28 8 97 950 7 = 40.15, (P = 0.10) 32 32 (P < 0.000 32 (P < 0.000 50000 32 11 41	400 146 1945 3, df = 1 E 01) 538 538 538 538 538 306 30 30 30 32 32 2218 df = 6 (F 138 138 138 01) \$/Disorr 27 53	41 1600 (P < 0.0 99 136 82 2 0 34 489 9 9 9 9 9 208	209 5485 00001); P 254 254 254 254 254 254 254 254 130 15 130 1462 001); P = 191 191	2.1% 34.8% 2.2% 2.2% 2.2% 0.8% 0.5% 0.5% 1.2.3% 1.8% 1.8% 1.5% 1.9%	2.81 [1.75, 4.52] 2.56 [1.82, 3.61] 1.15 [0.85, 1.56] 0.87 [0.64, 1.17] 0.83 [0.62, 1.12] 1.24 [0.85, 1.79] 196.00 [25.77, 1490.50] 10.33 [0.56, 191.23] 1.93 [0.40, 12, 3.77] 1.47 [0.93, 2.30] 6.10 [2.81, 13.28] 6.10 [2.81, 13.28] 6.10 [2.81, 13.28] 6.10 [2.81, 13.28] 6.10 [2.81, 13.28] 6.10 [2.81, 13.28]	
ariku et al. 2017 eshaw and Mossie, 2017 ubtotal (95% CI) otal events leterogeneity: Tau ² = 0.43; Chi est for overall effect $Z = 5.41$ (.1.4 Psychotic Symptoms/Dis luman 2003 didenwald et al. 2009 ungeri et al. 2019 ulloch et al. 2019 ulloch et al. 2019 ulloch et al. 2014 enebe et al. 2014 ubtotal (95% CI) otal events leterogeneity: Tau ² = 0.25; Chi est for overall effect: $Z = 1.66$ (.1.5 Psychopathy tiayih et al. 2020 ubtotal (95% CI) otal events leterogeneity: Not applicable est for overall effect: $Z = 4.56$ (.1.6 Unspecified Psychiatric med and Emad 1998 edaku 2014 unduma et al. 2017	19 59 858 858 269 263 263 263 28 8 97 950 ₽ = 0.10) 32 32 32 (P < 0.000 32 32 32 8 97 950 ₽ = 0.10) 32 32 32 8 8 97 950 8 97 950 950 950 950 950 950 950 950 950 950	40 146 1945 33, df = 1 E 538 538 538 538 538 538 538 538 538 538	41 1600 (P < 0.0 99 136 136 82 2 0 34 489 9 9 9 208 48 9 9 208 48 48 9 9 208 48 48 9 9 9 136 136 136 136 136 136 136 136	209 5485 254 254 254 254 254 254 254 254 254 300 15 1300 15 1300 15 1300 15 1300 15 3003 467	2.1% 34.8% 2.2% 2.2% 2.2% 0.5% 2.1% 12.3% 355%	2.81 [1.75, 4.52] 2.56 [1.82, 3.61] 1.15 [0.85, 1.56] 0.87 [0.64, 1.17] 0.83 [0.62, 1.12] 1.24 [0.85, 1.79] 196.00 [25.77, 1490.50] 10.33 [0.56, 191.82] 1.98 [1.24, 3.17] 1.47 [0.93, 2.30] 6.10 [2.81, 13.28] 6.10 [2.81, 13.28] 6.10 [2.81, 13.28] 6.10 [2.81, 13.28] 6.10 [2.81, 13.28] 6.10 [2.81, 13.28] 6.10 [2.81, 13.28]	
'ariku et al. 2017 'eshaw and Mossie, 2017 'uibtotal (95% CI) 'otal events leterogeneity: Tau ² = 0.43; Chi est for overall effect: $Z = 5.41$ (.1.4 Psychotic Symptoms/Dis luman 2003 Juman 2005 Juman 2005 Ju	19 59 858 80000 228 269 263 57 28 8 97 950 7 = 40.15, (P = 0.10) 32 32 (P < 0.000 32 (P < 0.000 50000 32 11 41	400 145 1945 538, df = 16 538 538 538 538 538 538 538 538 538 538	41 1600 (P < 0.0 99 136 82 2 0 34 489 9 9 9 9 9 208	209 5485 00001); P 254 254 254 254 254 254 254 130 1462 01); P = 191 191 191	2.1% 34.8% 2.2% 2.2% 2.2% 0.5% 2.1% 12.3% 85%	2.81 [1.75, 4.52] 2.56 [1.82, 3.61] 1.15 [0.85, 1.56] 0.87 [0.64, 1.17] 0.83 [0.62, 1.12] 1.24 [0.85, 1.79] 196.00 [25.77, 1490.50] 10.33 [0.56, 191.82] 1.98 [1.24, 3.17] 1.47 [0.93, 2.30] 6.10 [2.81, 13.28] 6.10 [2.81, 13.28] 6.10 [2.81, 13.28] 1.22 [0.40, 3.75] 2.85 [1.42, 5.70] 2.16 [1.47, 3.16] 2.12 [1.56, 2.89]	
ariku et al. 2017 eshaw and Mossie, 2017 uiubtotal (95% CI) fotal events est for overall effect. Z = 5.41 (.1.4 Psychotic Symptoms/Dis luman 2003 luman 2003 luman 2003 uluman 2019 Ulloch et al. 2019 ulloch et al. 2019 ulloch et al. 2014 ulenebe et al. 2014 ulenebe et al. 2014 events leterogeneity: Total applicable fest for overall effect. Z = 1.66 (.1.5 Psychopathy tayih et al. 2020 hotal events leterogeneity: Not applicable fest for overall effect. Z = 4.56 (.1.6 Unspecified Psychiatric med and Emad 1998 edaku 2014 unduma et al. 2017 bdenwald et al. 2005 tiayih et al. 2020	19 59 858 ₽ = 116.45 P < 0.0000 263 263 263 57 28 8 97 28 8 97 950 ₽ = 40.15, P = 0.10) 32 32 32 (P < 0.0000 Symptom 11 42 8 8 79	40 146 1945 33, df = 1 E 538 538 538 538 538 538 538 538 538 538	41 1600 ((P < 0.0 99 136 136 82 2 0 34 489 9 9 9 9 10 10 10 10 10 10 10 10 10 10	209 5485 254 254 254 254 254 254 254 254 254 300 15 1300 15 1300 15 1300 15 1300 15 3003 467	2.1% 34.8% 2.2% 2.2% 2.2% 0.5% 2.1% 12.3% 355%	2.81 [1.75, 4.52] 2.56 [1.82, 3.61] 1.15 [0.85, 1.56] 0.87 [0.64, 1.17] 0.83 [0.62, 1.12] 1.24 [0.85, 1.79] 196.00 [25.77, 1490.50] 10.33 [0.56, 191.82] 1.98 [1.24, 3.17] 1.47 [0.93, 2.30] 6.10 [2.81, 13.28] 6.10 [2.81, 13.28] 6.10 [2.81, 13.28] 6.10 [2.81, 13.28] 6.10 [2.81, 13.28] 6.10 [2.81, 13.28] 6.10 [2.81, 13.28]	
ariku et al. 2017 eshaw and Mossie, 2017 ubtotal (95% CI) otal events leterogeneity: Tau ² = 0.43; Chi est for overall effect $Z = 5.41$ (.1.4 Psychotic Symptoms/Dis luman 2003 diaman 2003 ubtoma 2003 ubtoma 2003 ubtoma 2003 ubtoma 2003 ubtoma 2003 ubtoma 2003 ubtoma 2003 ubtoma 2003 ubtoma 2003 ubtotal 2019 ubtotal (95% CI) otal events leterogeneity: Tau ² = 0.25; Chi est for overall effect: $Z = 1.66$ (.1.5 Psychopathy tayh et al. 2020 ubtotal (95% CI) otal events leterogeneity: Not applicable est for overall effect: $Z = 4.56$ (.1.6 Unspecified Psychiatric med and Emad 1998 edaku 2014 tunduma et al. 2017 ubtotal (95% CI)	19 59 858 ₽ = 116.45 P < 0.0000 263 263 263 57 28 8 97 28 8 97 950 ₽ = 40.15, P = 0.10) 32 32 32 (P < 0.0000 Symptom 11 42 8 8 79	40 146 1945 38, df = 18 538 538 538 538 538 538 306 30 30 32 32 2218 df = 6 (f 138 138 138 138 01) \$\$ J 050000 27 53 434 1401	41 1600 ((P < 0.0 99 136 136 82 2 0 34 489 9 9 9 9 10 10 10 10 10 10 10 10 10 10	209 5485 254 254 254 254 254 254 254 254 254 30 15 130 1462 01); * = 191 191 191 25 363 363 467 3284 191	2.1% 34.8% 2.2% 2.2% 2.2% 0.8% 0.5% 2.2% 1.8% 1.8% 1.8%	2.81 [1.75, 4.52] 2.56 [1.82, 3.61] 1.15 [0.85, 1.56] 0.87 [0.64, 1.17] 0.83 [0.62, 1.12] 1.24 [0.85, 1.79] 196.00 [25.77, 1490.50] 10.33 [0.56, 191.82] 1.98 [1.24, 317] 1.47 [0.93, 2.30] 6.10 [2.81, 13.28] 6.10 [2.81, 13.28]	
ariku et al. 2017 eshaw and Mossie, 2017 ubtotal (95% CI) otal events est for overall effect. Z = 5.41 (.1.4 Psychotic Symptoms/Dis luman 2003 luman 2003 ubtotal (95% CI) otal events etable et al. 2019 ulloch et al. 2019 ulloch et al. 2019 ulloch et al. 2019 ulloch et al. 2014 enebe et al. 2014 enebe et al. 2014 enebe et al. 2015 ubtotal (95% CI) otal events leterogeneity: Not applicable est for overall effect. Z = 4.56 (.1.6 Unspecified Psychiatric med and Emad 1998 edaku 2014 lunduma et al. 2017 idenwald et al. 2005 tiaxyih et al. 2020 ubtotal (95% CI) otal events leterogeneity: Tau ² = 0.05; Chi denwald et al. 2020 ubtotal (95% CI) otal events leterogeneity: Tau ² = 0.00; Chi	19 59 858 858 269 263 57 28 8 97 950 7 = 40.15, (P = 0.10) 32 32 (P < 0.000 5000 5000 7 = 40.15, (P = 0.10) 32 32 (P < 0.000 32 32 (P < 0.000 32 32 (P < 0.000 32 32 (P < 0.000 32 32 (P < 0.000 32 (P < 0.0000 32 (P < 0.00	40 146 1945 3, df = 1 (f) 538 538 538 538 538 306 30 30 32 32 2218 df = 6 (f) 138 138 138 138 01) s/Disorr 27 53 434 1401 118 2053	41 1600 (P < 0.0 99 136 136 22 0 34 489 9 9 9 9 208 48 9 9 15 370	209 5485 0001); * 254 254 254 254 254 254 254 254 254 254	2.1% 34.8% 2.2% 2.2% 2.2% 0.8% 0.5% 2.2% 1.8% 1.8% 1.8%	2.81 [1.75, 4.52] 2.56 [1.82, 3.61] 1.15 [0.85, 1.56] 0.87 [0.64, 1.17] 0.83 [0.62, 1.12] 1.24 [0.85, 1.79] 196.00 [25.77, 1490.50] 10.33 [0.56, 191.82] 1.98 [1.24, 317] 1.47 [0.93, 2.30] 6.10 [2.81, 13.28] 6.10 [2.81, 13.28]	
ariku et al. 2017 'eshaw and Mossie, 2017 'uisbrau (95% CI) 'otal events leterogeneity: Tau ² = 0.43; Chi est for overall effect: Z = 5.41 (1.4 Psychotic Symptoms/Dis luman 2003 Juman 200	19 59 858 858 269 263 57 28 8 97 950 7 = 40.15, (P = 0.10) 32 32 (P < 0.000 5000 5000 7 = 40.15, (P = 0.10) 32 32 (P < 0.000 32 32 (P < 0.000 32 32 (P < 0.000 32 32 (P < 0.000 32 32 (P < 0.000 32 (P < 0.0000 32 (P < 0.00	40 146 1945 3, df = 1 (f) 538 538 538 538 538 306 30 30 32 32 2218 df = 6 (f) 138 138 138 138 01) s/Disorr 27 53 434 1401 118 2053	41 1600 (P < 0.0 99 136 136 22 0 34 489 9 9 9 9 208 48 9 9 15 370	209 5485 0001); * 254 254 254 254 254 254 254 254 254 254	2.1% 34.8% 2.2% 2.2% 2.2% 0.8% 0.5% 2.2% 1.8% 1.8% 1.8%	2.81 [1.75, 4.52] 2.56 [1.82, 3.61] 1.15 [0.85, 1.56] 0.87 [0.64, 1.17] 0.83 [0.62, 1.12] 1.24 [0.85, 1.79] 196.00 [25.77, 1490.50] 10.33 [0.56, 191.82] 1.98 [1.24, 317] 1.47 [0.93, 2.30] 6.10 [2.81, 13.28] 6.10 [2.81, 13.28]	
ariku et al. 2017 (eshaw and Mossie, 2017 (ubtotal (95% CI) (iotal events leterogeneity: Tau ² = 0.43; Chi (est for overall effect: Z = 5.41)	19 59 858 858 269 263 57 28 8 97 950 7 = 40.15, (P = 0.10) 32 32 (P < 0.000 5000 5000 7 = 40.15, (P = 0.10) 32 32 (P < 0.000 32 32 (P < 0.000 32 32 (P < 0.000 32 32 (P < 0.000 32 32 (P < 0.000 32 (P < 0.0000 32 (P < 0.00	400 146 1945 30, df = 1 E 01) 538 538 538 538 538 538 538 538 538 538	41 1600 (P < 0.0 99 136 136 22 0 34 489 9 9 9 9 208 48 9 9 15 370	209 5485 0001); * 254 254 254 254 254 254 254 254 254 254	2.1% 34.8% 2.2% 2.2% 2.2% 2.2% 2.2% 2.5% 0.8% 0.5% 1.8% 1.8% 1.8% 1.8% 1.8% 1.9% 2.2% 2.2% 2.1% 2.1% 1.8%	2.81 [1.75, 4.52] 2.56 [1.82, 3.61] 1.15 [0.85, 1.56] 0.87 [0.64, 1.17] 0.83 [0.62, 1.12] 1.24 [0.85, 1.79] 196.00 [25.77, 1490.50] 10.33 [0.56, 191.24] 1.98 [1.24, 3.17] 1.47 [0.93, 2.30] 6.10 [2.81, 13.28] 6.10 [2.81, 13.28] 6.10 [2.81, 13.28] 1.22 [0.40, 3.75] 2.85 [1.42, 5.70] 2.16 [1.47, 3.16] 2.12 [1.56, 2.89] 1.54 [0.73, 3.23] 2.09 [1.69, 2.59]	
ariku et al. 2017 eshaw and Mossie, 2017 ubtotal (95% CI) otal events est for overall effect. $Z = 5.41$ (.1.4 Psychotic Symptoms/Dis luman 2003 luman 2003 ubtotal (95% CI) otal events et al. 2019 ulloch et al. 2019 ulloch et al. 2019 ulloch et al. 2019 ulloch et al. 2014 enebe et al. 2014 enebe et al. 2014 uenbe et al. 2015 ubtotal (95% CI) otal events leterogeneity: Not applicable est for overall effect. $Z = 1.66$ (.1.5 Psychopathy Itayih et al. 2020 ubtotal (95% CI) otal events leterogeneity: Not applicable est for overall effect. $Z = 4.56$ (.1.6 Unspecified Psychiatric med and Emad 1998 edaku 2014 lunduma et al. 2017 udenwald et al. 2020 ubtotal (95% CI) otal events leterogeneity: Tau ² = 0.00; Chi est for overall effect. $Z = 6.80$ (otal (95% CI)	19 59 858 F = 116.44 P < 0.0000 263 263 263 57 28 8 97 28 8 97 28 8 97 28 8 97 28 32 32 32 32 32 32 32 32 32 32 32 32 32	400 145 1945 3, df = 1E 01) 538 538 538 538 538 538 538 538 538 538	41 1600 (P < 0.0 99 93 136 82 2 0 34 489 9 9 9 9 9 9 9 9 9 9 9 9 9	209 5485 254 254 254 254 254 254 254 254 254 25	2.1% 34.8% 2.2% 2.2% 2.2% 0.5% 2.1% 12.3% 35% 1.8% 1.8% 1.8% 1.9% 9.7%	2.81 [1.75, 4.52] 2.56 [1.82, 3.61] 1.15 [0.85, 1.56] 0.87 [0.64, 1.17] 0.83 [0.62, 1.12] 1.24 [0.85, 1.79] 196.00 [25.77, 1490.50] 10.33 [0.56, 191.24] 1.98 [1.24, 3.17] 1.47 [0.93, 2.30] 6.10 [2.81, 13.28] 6.10 [2.81, 13.28] 6.10 [2.81, 13.28] 1.22 [0.40, 3.75] 2.85 [1.42, 5.70] 2.16 [1.47, 3.16] 2.12 [1.56, 2.89] 1.54 [0.73, 3.23] 2.09 [1.69, 2.59]	

Figure 2 Meta-analysis of included studies. M-H, Mantel-Haenszel.




Figure 3 Funnel plot of included studies.

While the results provided by this review are unlikely to be entirely accurate, they can provide a valid estimate until the evidence base expands enough to provide a systematic review with much lower heterogeneity.

One issue in particular is the variation in measuring khat consumption between studies. This review is limited as it has included both non-dependent and dependent khat use, which are likely to have varying association with psychiatric symptoms. Many studies simply described khat users as those who had chewed within the previous week or previous month, hence it was often difficult to distinguish between current users, long-term users and dependent users. This likely contributes to the high heterogeneity of the meta-analysis of this review, and should be considered in future primary and secondary research within this field.

Another limitation of this review is that it includes both psychiatric symptoms and psychiatric disorders under the term 'psychiatric symptoms'. Out of the 35 included studies, 28 measured psychiatric symptoms using screening tools, 5 measured psychiatric disorders using diagnostic tools and 2 used a mixture of both screening and diagnostic tools. This may also have contributed to the high heterogeneity of the meta-analysis.

One final limitation of this review is that it cannot demonstrate causation between the two variables. It would be useful for future research to include cohort studies. Many researchers hypothesise that khat use is the cause of psychiatric symptoms, with its active ingredients distorting the brain's cytoarchitecture and, therefore, increasing one's vulnerability to mental illness.^{78–80} Contrastingly, other researchers suggest that those with mental illness are more likely to chew khat as an attempt to self-medicate their symptoms.⁸¹ Long-term cohort studies would be able to assess which variable predisposes the other, monitor psychiatric symptoms that take time to manifest, and investigate how the prevalence of psychiatric symptoms changes as the duration of khat use increases.

CONCLUSIONS

This review combines 35 cross-sectional studies in the field of khat use, and using meta-analysis suggests that khat use is associated with a 122% increase in the prevalence of psychiatric symptoms, particularly psychiatric distress. The high heterogeneity of the meta-analysis is likely due to the wide variation between the studies within the evidence base. To perform a more accurate systematic review, further primary studies are needed with standardised measurements of variables, particularly khat consumption. Furthermore, the evidence base is unclear about causality within this relationship, another important focus for future research.

Acknowledgements The authors would like to acknowledge Dr Keith Brain (University of Birmingham) who originally suggested the topic idea, and Dr Jesse Young (University of Melbourne) for his feedback and enthusiasm towards the project. The authors would also like to thank the library team at the University of Birmingham for their help with the literature search. Finally, the authors would like to thank the Leslie James Topham fund (University of Birmingham Medical School) for providing funding towards living costs while this research was conducted.

Contributors BE planned the review and created the protocol. BE and NA completed the independent literature searches and created the summary of findings table. BE completed the meta-analyses including the sensitivity analysis. BE and NA independently assessed the quality of the included studies using the Newcastle-Ottawa Scale, and BE completed the GRADE scoring. BE wrote the systematic review and acts as the guarantor for this paper.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval Ethical approval was not necessary as only secondary data were used.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data sharing not applicable as no datasets generated and/or analysed for this study.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD

Betsy Edwards http://orcid.org/0000-0002-9553-7585

REFERENCES

- 1 European Monitoring Centre for Drugs and Drug Addiction. Khat drug profile (date unknown). Available: https://www.emcdda.europa. eu/publications/drug-profiles/khat/de [Accessed 01 Dec 2020].
- 2 Wabe NT. Chemistry, pharmacology, and toxicology of khat (Catha edulis Forsk): a review. *Addict Health* 2011;3:137–49.

Open access

- 3 World Health Organisation. Khat chewing in Yemen: turning over a new leaf, 2008. Available: https://www.who.int/bulletin/volumes/86/ 10/08-011008/en/ [Accessed 01 Dec 2020].
- 4 Al-Juhaishi T, Al-Kindi S, Gehani A. Khat: a widely used drug of abuse in the horn of Africa and the Arabian Peninsula: review of literature. *Qatar Med J* 2012;2012:1–6.
- 5 Cochrane L, O'Regan D. Legal harvest and illegal trade: trends, challenges, and options in khat production in Ethiopia. *Int J Drug Policy* 2016;30:27–34.
- 6 Douglas H, Boyle M, Lintzeris N. The health impacts of khat: a qualitative study among Somali-Australians. *Med J Aust* 2011;195:666–9.
- 7 Widmann M, Warsame AH, Mikulica J, *et al.* Khat Use, PTSD and Psychotic Symptoms among Somali Refugees in Nairobi - A Pilot Study. *Front Public Health* 2014;2:71.
- 8 Cox G, Rampes H. Adverse effects of khat: a review. *Adv. psychiatr. treat* 2003;9:456–63.
- 9 Hassan NAGM, Gunaid AA, Murray-Lyon IM. Khat (Catha edulis): health aspects of khat chewing. *East Mediterr Health J* 2007;13:706–18.
- 10 Young JT, Butt J, Hersi A, et al. Khat dependence, use patterns, and health consequences in Australia: an exploratory study. J Stud Alcohol Drugs 2016;77:343–8.
- 11 Omar YS, Jenkins A, Altena MvanR, et al. Khat use: what is the problem and what can be done? *Biomed Res Int* 2015;2015:1–7.
- 12 Anderson DM, Carrier NCM. Khat: social harms and legislation, 2011. Available: https://assets.publishing.service.gov.uk/ government/uploads/system/uploads/attachment_data/file/116260/ occ95.pdf
- 13 Edwards B, Atkins N. Exploring the association between khat use and psychiatric symptoms: a systematic review, 2021. Available: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID= 224510
- 14 PRISMA. PRISMA checklist, 2021. Available: http://www.prismastatement.org/PRISMAStatement/Checklist [Accessed 3 May 2021].
- 15 Medical Subject Headings. Us national library of medicine (2021), 2021. Available: https://meshb.nlm.nih.gov/search [Accessed 19 September].
- 16 Sanati A. Does suicide always indicate a mental illness? London J Prim Care 2009;2:93–4.
- 17 The Ottawa Hospital. Newcastle-Ottawa quality assessment scale, 2021. Available: http://www.ohri.ca/programs/clinical_epidemiology/ oxford.asp [Accessed 19 Sep 2021].
- 18 Modesti PA, Reboldi G, Cappuccio FP, et al. Panethnic differences in blood pressure in Europe: a systematic review and meta-analysis. PLoS One 2016;11:e0147601.
- 19 Deeks JJ, Higgins JPT, Altman DG. Chapter 10: analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, et al, eds. Cochrane Handbook for systematic reviews of interventions. version 6.2. Cochrane, 2021. www.training.cochrane. org/handbook
- 20 Sambunjak D, Cumpston M, Watts C. Module 6: analysing the data. in: cochrane interactive learning: conducting an intervention review. Cochrane, 2017. Available: https://training.cochrane.org/ interactivelearning/module-6-analysing-data [Accessed 05 Nov 2021].
- 21 Schünemann H, Brozek J, Guyaa G. The grade Handbook, 2013. Available: https://gdt.gradepro.org/app/handbook/handbook.html#h. svwngs6pm0f2 [Accessed 2 May 2021].
- 22 Nakajima M, Hoffman R, al'Absi M. Level of khat dependence, use patterns, and psychosocial correlates in Yemen: a cross-sectional investigation. *East Mediterr Health J* 2017;23:161–7.
- 23 al'Absi M, Khalil NS, Al Habori M, et al. Effects of chronic khat use on cardiovascular, adrenocortical, and psychological responses to stress in men and women. Am J Addict 2013;22:99–107.
- 24 Boka A, Alemu M, Fantu A. Magnitude of substance induced psychosis among adolescents in amanuel mental specialised Hospital Addis Ababa, Ethiopia. J Drug Alcohol Res 2021;10:236126 https://www.ashdin.com/articles/magnitude-of-substance-inducedpsychosis-among-adolescents-in-amanuel-mental-specializedhospital-addis-ababa-ethiopia-81031.html
- 25 Hassen MT, Soboka M, Widmann M, et al. Khat use patterns, associated features, and psychological problems in a Khat-Treatment-Seeking student sample of Jimma University, southwestern Ethiopia. Front Public Health 2021;9:645980.
- 26 Al Bahhawi T, Albasheer OB, Makeen AM, et al. Depression, anxiety, and stress and their association with khat use: a crosssectional study among Jazan university students, Saudi Arabia. *Neurospcyhiatr Dis Treat* 2018;14:2755–61.
- 27 Nakajima M, Jebena MG, Taha M, *et al*. Correlates of khat use during pregnancy: a cross-sectional study. *Addict Behav* 2017;73:178–84.

- 28 Mains D, Hadley C, Tessema F. Chewing over the future: khat consumption, anxiety, depression, and time among young men in Jimma, Ethiopia. *Cult Med Psychiatry* 2013;37:111–30.
- 29 Bhui K, Warfa N. Trauma, khat and common psychotic symptoms among Somali immigrants: a quantitative study. *J Ethnopharmacol* 2010;132:549–53.
- 30 Woods D. Mental health and wellbeing of Somalis in the United Kingdom, 2004. Available: https://www.semanticscholar.org/paper/ Mental-health-and-well-being-of-Somalis-in-the-Woods/2c4a853a 72d029c785575880fcf8a0870d7d0b7c
- 31 Dawud B, Yeshigeta E, Negash A. Substance use disorders and associated factors among adult psychiatric patients in Jimma town, Southwest Ethiopia, 2017, community-based cross-sectional study. *Clin Med Insights Psychiatry* 2017;12.
- 32 Alebachew W, Semahegn A, Ali T, et al. Prevalence, associated factors and consequences of substance use among health and medical science students of Haramaya University, eastern Ethiopia, 2018: a cross-sectional study. *BMC Psychiatry* 2019;19:343.
- 33 Yitayih Y, Abera M, Tesfaye E, et al. Substance use disorder and associated factors among prisoners in a correctional institution in Jimma, Southwest Ethiopia: a cross-sectional study. BMC Psychiatry 2018;18:314.
- 34 Kroll J, Yusuf AI, Fujiwara K. Psychoses, PTSD, and depression in Somali refugees in Minnesota. Soc Psychiatry Psychiatr Epidemiol 2011;46:481–93.
- 35 Ahmed AG, Salib E, Emad S. The khat users: a study of khat chewing in Liverpool's Somali men. *Med Sci Law* 1998;38:165–9.
- 36 Belew M, Kebede D, Kassaye M, *et al.* The magnitude of khat use and its association with health, nutrition and socio-economic status. *Ethiop Med J* 2000;38:11–26.
- 37 Numan N. Exploration of adverse psychological symptoms in Yemeni khat users by the symptoms Checklist-90 (SCL-90). Addiction 2004;99:61–5.
- 38 Odenwald M, Neuner F, Schauer M, et al. Khat use as risk factor for psychotic disorders: a cross-sectional and case-control study in Somalia. BMC Med 2005;3:5.
- 39 Deyessa N, Berhane Y, Alem A, et al. Depression among women in rural Ethiopia as related to socioeconomic factors: a communitybased study on women in reproductive age groups. Scand J Public Health 2008;36:589–97.
- 40 Odenwald M, Hinkel H, Schauer E, *et al.* Use of khat and posttraumatic stress disorder as risk factors for psychotic symptoms: a study of Somali combatants. *Soc Sci Med* 2009;69:1040–8.
- 41 Damena T, Mossie A, Tesfaye M. Khat chewing and mental distress: a community based study, in jimma City, southwestern Ethiopia. *Ethiop J Health Sci* 2011;21:37–45.
- 42 Tulloch AD, Frayn E, Craig TKJ, et al. Khat use among Somali mental health service users in South London. Soc Psychiatry Psychiatr Epidemiol 2012;47:1649–56.
- 43 Dessie Y, Ebrahim J, Awoke T. Mental distress among university students in Ethiopia: a cross sectional survey. *Pan Afr Med J* 2013;15:95.
- 44 Fekadu W, Haregwoin M, Kibrom H. Magnitude of mental illness and associated factors among Holy water users at Entoto ST Mary church, Addis Ababa, Ethiopia, 2014. *J Psychiatry* 2014;18:285.
- 45 Dachew B, Bifftu B, Tadesse B. Khat use and its determinants among university students in Northwest Ethiopia: a multivariable analysis. *Int J Med Sci Public Health* 2014;4:1.
- 46 Soboka M, Tesfaye M, Feyissa GT, et al. Khat use in people living with HIV: a facility-based cross-sectional survey from South West Ethiopia. *BMC Psychiatry* 2015;15:69.
- 47 Zenebe Y, Feyissa GT, Krahl W. Khat use in persons with mental illness in Southwest Ethiopia: a cross-sectional study. *J Addict Res Ther* 2015;6:3.
- 48 El-Setouhy M, Alsanosy RM, Alsharqi A. Khat dependency and psychophysical symptoms among chewers in Jazan region, Kingdom of Saudi Arabia. *BioMed Res Int* 2016;1:2642506.
- 49 Hersi L, Tesfay K, Gesesew H, et al. Mental distress and associated factors among undergraduate students at the University of Hargeisa, Somaliland: a cross-sectional study. Int J Ment Health Syst 2017;11:39.
- 50 Hunduma G, Girma M, Digaffe T, et al. Prevalence and determinants of common mental illness among adult residents of Harari regional state, eastern Ethiopia. Pan Afr Med J 2017;28:262.
- 51 Kerebih H, Ajaeb M, Hailesilassie H. Common mental disorders among medical students in Jimma University, Southwest Ethiopia. *Afr Health Sci* 2017;17:844–51.
- 52 Mossie A, Kindu D, Negash A. Prevalence and severity of depression and its association with substance use in Jimma town, Southwest Ethiopia. *Depress Res Treat* 2016;2016:3460462.

- 53 Soboka M, Gudina EK, Tesfaye M. Psychological morbidity and substance use among patients with hypertension: a hospital-based cross-sectional survey from South West Ethiopia. *Int J Ment Health Syst* 2017;11:5.
- 54 Tariku GH, Zerihun AA, Bisrat ZS, et al. Mental distress and its associated factors among students of Mizan AMAN health science College, Ethiopia. J. of Medical Sciences 2017;17:61–7.
- 55 Wondemagegn AT, Cheme MC, Kibret KT. Perceived psychological, economic, and social impact of khat chewing among adolescents and adults in Nekemte town, East Welega zone, West Ethiopia. *Biomed Res Int* 2017;2017:7427892.
- 56 Yeshaw Y, Mossie A. Depression, anxiety, stress, and their associated factors among Jimma university staff, Jimma, Southwest Ethiopia, 2016: a cross-sectional study. *Neuropsychiatr Dis Treat* 2017;13:2803–12.
- 57 Bedaso A, Kediro G, Yeneabat T. Factors associated with depression among prisoners in southern Ethiopia: a cross-sectional study. *BMC Res Notes* 2018;11:637.
- 58 Adraro W, Kerebih H, Tesema W, et al. Nearly three in every five prisoners experience common mental disorders (CMDs) in Jimma correctional institution; south-west Ethiopia. BMC Public Health 2019;19:1559.
- 59 Ongeri L, Kirui F, Muniu E, *et al.* Khat use and psychotic symptoms in a rural khat growing population in Kenya: a household survey. *BMC Psychiatry* 2019;19:137.
- 60 Athafie SÁ, Muluneh NY, Getahun KA, *et al.* Depression, anxiety, stress, and associated factors among khat chewers in Amhara region, Northwest Ethiopia. *Depress Res Treat* 2020;2020:1–12.
- 61 Hajure M, Dibaba B, Shemsu S. Psychological distress among health care workers in health facilities of Mettu town during COVID-19 outbreak, Southwest Ethiopia, 2020. Front Psychiatry 2021;10:740.
- 62 Hambisa M, Derese A, Abdeta T. Depressive symptoms among Haramaya university students in Ethiopia: a cross-sectional study. *Depress Res Treat* 2020;1:5027918.
- 63 Kelemu R, Kahsay A, Ahmed K. Prevalence of mental distress and associated factors among Samara university students, northeast Ethiopia. *Depress Res Treat* 2020;1:7836296.
- 64 Mekuriaw B, Belayneh Z, Yitayih Y. Magnitude of khat use and associated factors among women attending antenatal care in Gedeo zone health centers, southern Ethiopia: a facility based cross sectional study. *BMC Public Health* 2020;20:110.
- 65 Yitayih Y, Soboka M, Tesfaye E, et al. A cross-sectional study of psychopathy and khat abuse among prisoners in the correctional institution in Jimma, Ethiopia. PLoS One 2020;15:e0227405.
- 66 Haile K, Sahile AT. Depressive symptoms in primary health care Attendees in Sebeta town, Ethiopia: prevalence, associated factors, and detection by health workers. *Sci Prog* 2021;104:1–15.
- 67 Hambisa S, Siraj J, Mesafint G, et al. Assessment of psychological distress and associated factors among hospitalized patients during

the COVID-19 pandemic at selected hospitals in Southwest Ethiopia. *Neuropsychiatr Dis Treat* 2021;17:885–92.

- 68 Melaku L, Mossie A, Negash A. Stress among medical students and its association with substance use and academic performance. J Biomed Educ 2015;1:149509.
- 69 Mekuriaw B, Zegeye A, Molla A, *et al.* Prevalence of common mental disorder and its association with khat chewing among Ethiopian college students: a systematic review and meta-analysis. *Psychiatry* J 2020;2020:1462141.
- 70 Richardson M, Garner P, Donegan S. Interpretation of subgroup analyses in systematic reviews: a tutorial. *Clinical Epidemiology and Global Health* 2019;7:192–8.
- 71 World Health Organisation. Depression and other common mental disorders; global health estimates, 2017. Available: https://apps.who. int/iris/bitstream/handle/10665/254610/WHO-MSD-MER-2017.2eng.pdf [Accessed 05 Nov 2021].
- 72 Bartjes J, Lochner C, Saal W, et al. Prevalence and sociodemographic correlates of common mental disorders among first-year university students in post-apartheid South Africa: implications for a public mental health approach to student wellness. BMC Public Health 2019;19:922.
- 73 Mental Health Foundation. Mental health statistics: refugees and asylum seekers (NO date). Available: https://www.mentalhealth.org. uk/statistics/mental-health-statistics-refugees-and-asylum-seekers [Accessed 05 Nov 2021].
- 74 Public Health England. Mental health: migrant health guide, 2017. Available: https://www.gov.uk/guidance/mental-health-migranthealth-guide [Accessed 05 Nov 2021].
- 75 Murthy RS, Lakshminarayana R. Mental health consequences of war: a brief review of research findings. *World Psychiatry* 2006;5:25–30.
- 76 Durcan G, Zwemstra JC. Mental health in prison (NO date). Available: https://www.euro.who.int/__data/assets/pdf_file/0017/249200/ Prisons-and-Health,-11-Mental-health-in-prison.pdf [Accessed 05 Nov 2021].
- 77 Price PC, Jhangiani R, Chiang IA. Chapter 6: Nonexperimental research. In: Price PC, Jhangiani R, Chiang IA, et al, eds. Research methods in psychology. 3rd ed, 2017. https://opentext.wsu.edu/ carriecuttler/
- 78 Echoru I, Bukenya EEM, Masilili G, et al. Khat distorts the prefrontal cortex histology and function of adult Wistar rats. Anat J Afr 2018;7:1121–31.
- 79 Fluyau D, Mitra P, Lorthe K. Antipsychotics for amphetamine psychosis. A systematic review. *Front Psychiatry* 2019;10:740.
- 80 Mullen J, Richards J, Crawford A. "Amphetamine related psychiatric disorders", In: Statpearls. Florida, USA: Statpearls Publishing, 2021.
- 81 Odenwald M, al'Absi M, al'Absi M. Khat use and related addiction, mental health and physical disorders: the need to address a growing risk. *East Mediterr Health J* 2017;23:236–44.

Supplementary Material 1: Search strategies

Ovid MEDLINE, Embase and APA PsycInfo	Search Strategy
#1	Khat.ab or khat.ti or qat.ab or qat.ti or qaad.ab or qaad.ti or catha.ab or catha.ti or miraa.ab or miraa.ti or mairungi.ab or mairungi.ti
#2	Depression.ab or depression.ti or anxiety.ab or anxiety.ti or bipolar.ab or bipolar.ti or mania.ab or mania.ti or psych*.ab or psych*.ti or schiz*.ab or schiz*.ti or mental.ab or mental.ti or hallucinations.ab or hallucinations.ti or delusions.ab or delusions.ti
#3	1 and 2
CINAHL	
#1	TI khat OR AB khat OR TI qat OR AB qat OR TI qaad OR AB qaad OR TI catha OR AB catha OR TI miraa OR AB miraa OR TI mairungi OR AB mairungi
#2	TI depression OR AB depression OR TI anxiety OR AB anxiety OR TI bipolar OR AB bipolar OR TI mania OR AB mania OR TI psych* OR AB psych* OR TI schiz* OR AB schiz*
#3	TI mental OR AB mental OR TI hallucinations OR AB hallucinations OR TI delusions OR AB delusions
#4	2 OR 3
#5	1 AND 4
Scopus	
#1	(TITLE (khat) OR ABS (khat) OR TITLE (qat) OR ABS (qat) OR TITLE (qaad) OR ABS (qaad) OR TITLE (catha) OR ABS (catha) OR TITLE (miraa) OR ABS (miraa) OR TITLE (mairungi) OR ABS (mairungi))
#2	(TITLE (depression) OR ABS (depression) OR TITLE (anxiety) OR ABS (anxiety) OR TITLE (bipolar) OR ABS (bipolar) OR TITLE (mania) OR ABS (mania) OR TITLE (psych*) OR ABS (psych*) OR TITLE (schiz*) OR ABS (schiz*) OR TITLE (mental) OR ABS (mental) OR TITLE (hallucinations) OR ABS (hallucinations) OR TITLE (delusions) OR ABS (delusions))

#3	1 AND 2
Proquest	
#1	ab(khat) OR ti(khat) OR ab(qat) OR ti(qat) OR ab(qaad) OR ti(qaad) OR ab(catha) OR ti(catha) OR ab(miraa) OR ti(miraa)
#2	ab(mairungi) OR ti(mairungi)
#3	ab(depression) OR ti(depression) OR ab(anxiety) OR ti(anxiety) OR ab(bipolar) OR ti(bipolar) OR ab(mania) OR ti(mania) OR ab(psych*) OR ti(psych*)
#4	ab(schiz*) OR ti(schiz*) OR ab(mental) OR ti(mental) OR ab(hallucinations) OR ti(hallucinations) OR ab(delusions) OR ti(delusions)
#5	1 OR 2
#6	3 OR 4
#7	5 AND 6 (limit: full texts only)

Supplementary Material 2: Summary of Findings Table

Study	Population	Sample	Criteria for 'Khat User'	Psychiatric Measure [*]	Results
Ahmed and Emad 1998 [35]	Somali immigrants living in Liverpool	Convenience sample of 52 Khat users = 27	Unspecified	GHQ-28	- 11/27 khat users experienced psychiatric dysfunction, compared to 9/25 non-users (p=0.72)
Belew et al. 2000 [36]	Individuals aged 15+ from a specified community in Ethiopia	Random sample of 1200 participants Khat users = 326	Anyone who has chewed khat within the last 30 days	SRQ	 100/326 khat-users experienced mental distress, compared to 28/554 non-users (OR = 8.31, 5.20-13.31, p=0.00) 89/294 long-term users (over 2 years) experienced mental distress, compared to 28/554 never-users (OR = 8.14, 5.06-13.17, p=0.00)
Numan 2003 [37]	Yemeni population	Random sample of 800 participants Khat users = 67.9%	Frequent use – 4-6 days a week Heavy use – use everyday	SCL-90	 No significant differences (at p<0.05) in psychiatric symptoms: obsession-compulsion, depression, anxiety, paranoid ideation, psychoticism Khat users had less phobic anxiety (37.7% vs 55.5%, p<0.05)
Odenwald et al. 2005 [38]	'General population' of Somalia	Random sample of 4854 Khat users = 78% of those with psychiatric issues, 4% of those without	Number of bundles in previous week recorded	CIDI, PANSS	- More positive screened individuals (mental problems severe enough to prevent employment or household tasks) chewed khat than negative screened individuals (46.6% vs 29.9%, p<0.001)
Deyessa et al. 2008 [39]	Women of reproductive age in rural Ethiopia	Random sample of 3200 Khat users = 40%	At least once per week	CIDI, ICD-10	 - 5.9% of regular users had had a depressive episode in the last 12 months, compared to 3.1% of non-regular users (less than once per month) and 3.6% of non-users - AOR for regular vs non-users is 1.35 (0.92-1.99)

Odenwald et al. 2009 [40]	Armed combatants in Somali	8124 armed individuals (not random as still in conflict at time of study) Khat users = 36.4%	Anyone who has chewed khat within the last week	CIDI	- 8.9% of khat users experienced paranoid ideation compared to 2.6% of non-users
Damena et al. 2011 [41]	Adults in Jimma City, Ethiopia	Random sample of 1308 Khat users = 38%	Uses WHO-validated substance abuse questionnaire, but unsure what is classified as 'khat user'	SRQ-20	- 49/136 long-term khat chewers experienced mental distress, compared to 108/317 short-term khat chewers (less than two years), and 153/747 non-users
Tulloch et al. 2012 [42]	Adult Somali khat users living in South London	Secondary data based on 172 eligible Somali mental health patients Khat users = 47%	Anyone who has chewed khat within the last year	Diagnosis provided by service records	- 28/30 khat users experienced psychosis compared to 2/30 non-users (p<0.001)
Dessie et al. 2013 [43]	Students in Ethiopia	Random sample of 413 Khat users = 43%	Anyone who has ever used khat	SRQ-20	- 59/185 khat users experienced mental distress compared to 34/245 non-users (AOR = 2.23, 1.14-4.35, p<0.05)
Fekadu 2014 [44]	Holy water users from Entoto St Mary Church, Ethiopia	409 individuals selected using systematic random sampling Daily khat users = 12.7%	Khat use recorded as 'never' or 'daily', although no indication of the duration of daily usage	BPRS	- 42/53 daily khat-users experienced symptoms of mental illness compared to 208/363 non-users (AOR = 2.85, 1.42-5.70)
Widmann et al. 2014 [7]	Male Somali refugees living in a disadvantaged	Convenience sample of 33 users and 15 comparable non-users	SDS	CIDI, MINI	- 24% of khat users had psychotic symptoms compared to 0% of non-chewers (p=0.044)

	urban settlement in Kenya	Khat users = 69%			
Dachew et al. 2015 [45]	Undergraduate students from Gondar University, Ethiopia	872 patients selected using stratified, random sampling Current khat users = 16%	Questionnaire identifying 'current use'	SRQ-20	- 63/114 current khat users had mental distress, compared to 279/722 non-users (OR=1.96, 1.32-2.92, p=0.02)
Soboka et al. 2015 [46]	HIV patients at a specified facility in South West Ethiopia	All eligible adults invited to participate Sample of 389 Khat users = 93	Anyone who has chewed khat within the last month	K-6	- 52/93 khat-users experienced psychological distress, compared to 124/296 non-users (OR = 1.76, 1.10-2.82)
Zenebe et al. 2015 [47]	Psychiatric outpatients in Ethiopia	365 adult psychiatric outpatients of a specified hospital within 2-week study period Khat use = 64.4%	Anyone who has used khat within the last 30 days	Psychiatric diagnosis from psychiatric records	 - 58/235 khat users had a major depressive disorder compared to 46/130 non-users (AOR = 1.43, 0.74-2.77) - 97/235 khat users had schizophrenia compared to 34/130 non-users (AOR = 0.87, 0.45-1.68)
El-Setouhy et al. 2016 [48]	Jazan region of Saudi Arabia	Volunteer sample of 70 males Khat dependent = 52.2%	SDS	Q16	 - 13/35 dependent users felt depressed compared to 7/32 non-dependent users (OR = 2.30, 0.7-6.8) - 20/35 dependent users felt anxious compared to 10/32 non-dependent users (OR = 3.50, 1.2-10.0)
Hersi et al. 2017 [49]	Students in Somaliland	Stratified random sample of 570 Khat users = 19%	Use in last 12 months	SRQ-20	- 32% of khat users experienced psychological distress, compared to 17% of non-users (AOR = 2.87, 1.26-6.56)
Hunduma et al. 2017 [50]	Adults in Ethiopia	Random sample of 968 Khat users = 48%	Khat use in last 3 months	SRQ-20	- 86/434 khat users had a common mental disorder, compared to 48/467 non-users (OR = 2.16, 1.47-3.16)

Kerebih et al. 2017 [51]	Medical students in Ethiopia	Stratified random sample of 305	Anyone who has ever used khat	SRQ-20	- 18/26 khat users experienced mental distress compared to 84/264 non-users (AOR = 6.91, 1.88-25.42,
Mossie et al. 2016 [52]	Adults in Ethiopia	Khat users = 9% Random sample of 650 Khat users = 34%	Khat use within the last 30 days	BDI	p=0.004) - 104/200 khat users had depression compared to 67/390 non-users (AOR = 10.07, 5.56-18.25)
Soboka et al. 2017 [53]	Adults with hypertension at a specified clinic in South West Ethiopia	All eligible adults invited to participate Sample of 396 Khat users = 79	Anyone who has chewed khat within the last month	K-6	- 27/72 current khat-users experienced psychological distress, compared to 98/324 non-users
Tariku et al. 2017 [54]	Students at a health sciences college in Ethiopia	Stratified random sample of 317 Khat users = 13%	Anyone who has ever used khat	Not specified	- 19/40 khat users experienced mental distress compared to 71/168 non-users (AOR = 2.29, 1.04-5.04)
Wondemage gn et al. 2017 [55]	Adolescents and adults in Nekemte town, West Ethiopia	Random sample of 359 participants Khat users = 49%	Anyone who has chewed khat within the last 30 days	DSM-IV	- 108/172 users experienced depression compared to 15/182 non-users (AOR = 25.36, 12.13-53.05, p=0.000) - 79/172 users experienced anxiety compared to 26/182 non-users (AOR = 5.49, 3.04-9.96, p=0.000)
Yeshaw and Mossie 2017 [56]	Staff of Jimma University, Ethiopia	Random sample of 363 Khat users = 41%	Anyone who has ever used khat	DASS-21	 - 54/145 khat users had depression compared to 27/209 non-users (AOR = 4.99, 2.57-9.69) - 43/145 khat users had anxiety compared to 25/209 non-users (AOR = 2.94, 1.52-5.66) - 59/145 khat users had psychological stress compared to 41/209 non-users (AOR = 2.78, 1.49-5.21)
Bedaso et al. 2018 [57]	Prisoners in Ethiopia	Random sample of 335 Khat users = 14%	Unspecified, but appears to be chewing khat before incarceration	PHQ-9	- 36/48 khat users had depression, compared to 153/287 non-users (AOR = 2.48, 1.05-5.86, p=0.039)
Adraro et al. 2019 [58]	Prisoners in Ethiopia	Random sample of 300 Khat users = 46%	Anyone who has ever used khat	SRQ-20	- 119/139 khat users experienced mental distress, compared to 69/161 non-users (AOR = 4.33, 2.02-9.27, p<0.001)

Ongeri et al. 2019 [59]	Khat-growing regions of Kenya	Random sample of 831 individuals aged 10+ Khat users = 36.8%	Unspecified	PSQ	- 18.6% of khat users experienced at least one psychotic symptom compared to 15.6% of non-users (p=0.26)
Atnafie et al. 2020 [60]	Khat chewers in Amhara region of Ethiopia	Convenience sample of 508 participants Khat dependent = 43%	SDS	DASS-21	 - 33/207 khat-dependent users experienced stress compared to 57/271 non-dependent users (AOR = 1.70, 0.98-2.95) - 146/207 khat-dependent users experienced anxiety compared to 133/271 non-dependent users (AOR = 2.47, 1.57-3.81) - 41/207 khat-dependent users experienced depression compared to 80/271 non-users (AOR = 6.28, 1.67-23.61)
Hajure et al. 2020 [61]	Healthcare providers in Ethiopia	Convenience sample of 127 Khat users = 45%	Khat use in last three months	IES-R	- 37/57 khat users experienced psychological stress, compared to 14/70 non-users (AOR = 5.74, 1.83-18.1, p<0.001)
Hambisa et al. 2020 [62]	Students in Ethiopia	Random sample of 1022 Khat users = 24%	Khat use within last month	BDI	- 84/241 khat users had depressive symptoms compared to 190/781 non-users (OR = 1.60, 1.22-2.27)
Kelemu et al. 2020 [63]	Students in Ethiopia	Random sample of 404 Khat users = 27%	Anyone who has ever used khat	SRQ-20	- 70/111 khat users experienced mental distress, compared to 145/293 non-users (AOR = 3.09, 1.74-5.50)
Mekuriaw et al. 2020 [64]	Pregnant women in Ethiopia	Random sample of 845 Khat users = 11%	Investigates usage but unclear what quantifies a 'current khat user'	SRQ-20	- 39/71 khat users experienced mental distress, compared to 149/647 non-users (AOR = 3.57, 2.06-6.18, p=0.001)
Yitayih et al. 2020 [65]	Prisoners in a correctional	Random sample of 336 Khat users = 138	DAST-10	PCL:SV	- 32/138 khat users met the criteria for psychopathy, compared to 9/191 non-users

	institution in Jimma, Ethiopia				- 16/138 khat users had mental illness, compared to 15/191 non-users
Haile and Sahile, 2021 [66]	Adult primary healthcare attendees in Ethiopia	Stratified and systematic random sample of 384 Khat users = 39%	Unspecified	PHQ-9	- 67/108 khat users had depressive symptoms, compared to 40/276 non-users (AOR = 5.43, 2.55-11.56, p<0.01)
Hambisa et al. 2021 [67]	Hospitalised patients in Ethiopia	Systematic sample of 337 Khat users = 18%	Unspecified; discusses 'current khat use' and 'khat use in the previous three months'	K10	- 49/59 khat users experienced psychological distress, compared to 146/278 non-users (AOR = 4.16, 1.67-10.35)
Melaku et al. 2021 [68]	Medical students in Ethiopia	Systematic random sample of 260 Khat users = 22%	Anyone who has ever used khat	DASS-21	 - 37/56 khat users had depression, compared to 99/204 non-users (OR = 2.07, 1.11-3.83) - 41/56 khat users had anxiety, compared to 117/204 non-users (OR = 2.03, 1.06-3.91) - 30/56 khat users had psychological stress, compared to 75/204 non-users (OR = 1.99, 1.09-3.61)

*List of abbreviated screening tools: GHQ-28 (General Health Questionnaire-28, for mental disorders), SRQ-20 (Self-Reporting Questionnaire - 20 items, for mental distress), SCL-90 (Symptom Checklist - 90 items, for psychological symptoms), CIDI (Composite International Diagnostic Interview - for psychiatric disorders), PANSS (Positive and Negative Syndrome Scale - for schizophrenia), ICD-10 (International Classification of Diseases, 10th revision), BPRS (Brief Psychiatric Rating Scale - for depression, anxiety and hallucinations), SDS (Severity of Dependence Scale), MINI (Mini International Psychiatric Review), K-6 (Kessler Psychological Distress Scale - 6 questions), Q16 (Questionnaire 16 for neurotoxic symptoms), BDI (Beck's Depression Inventory), DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th edition), DASS-21 (The Depression, Anxiety and Stress Scale - 21 Items), PHQ-9 (Patient Health Questionnaire - 9 items, for depression), PSQ (Psychosis Screening Questionnaire), IES-R (Impacts of Events Scale - Revised), DAST-10 (Drug Abuse Screening Test-10), PCL:SV (Psychopathy Checklist: Screening Version), K10 (Kessler Psychological Distress Scale - 10 questions)

Supplementary Material 3: Quality of assessment of primary studies using Newcastle-Ottawa scale [17-18].

Study	Selection (/5)	Comparability (/2)	Outcome (/3)	Overall Score (/10)	Comments
Ahmed and Emad 1998	1	2	1	4	 Non-random sample No justification of sample size 100% response rate Questionnaire described in insufficient detail no definition of khat use No significant differences in baseline characteristics between khat users and non-users Uses self-report No details of statistical analysis and no confidence intervals provided
Belew et al. 2000	3	2	2	7	 Insufficient details of non-responders; no baseline characteristics provided Questionnaire described in limited detail but methods do define current, past and never khat use
Numan 2003	3	1	1	5	 Sample size not justified Eight non-respondents excluded because of incomplete data Non-validated but described method of khat usage data collection Only controlled variable seems to be Yemeni nationality No confidence intervals included
Odenwald et al. 2005	3	2	2	7	 Sample size not justified No details of non-responders Non-validated but described method of khat usage data

					collection - Uses clinical interviews - No confidence intervals included
Deyessa et al. 2008	3	2	3	8	 Providers reasons for non-responders but not characteristics Non-validated but described method of khat usage data collection Clinical interview
Odenwald et al. 2009	2	2	2	6	 Sample size not justified No details of non-responders Non-validated but described method of khat usage data collection Uses self-report
Damena et al. 2011	4	1	1	6	 Providers reasons for non-responders but not characteristics Uses WHO-validated khat use measurement tool despite definition of 'khat user' being unclear within the study Only controlled variable seems to be region (Jimma City) Uses self-report No confidence intervals included
Tulloch et al. 2012	4	2	2	8	 Entire eligible sample used Missing information discussed Non-validated but described method of khat usage data collection No confidence intervals included
Dessie et al. 2013	3	2	2	7	 No details of non-responders Non-validated but described method of khat usage data collection

					- Uses self report
Fekadu 2014	2	2	2	6	 No details of non-responders Khat usage data collection described insufficiently: 'daily' or 'never' Uses self-report
Widmann et al. 2014	2	2	3	7	 Opportunity sample Sample size not justified No details of non-responders Clinical interview
Dachew et al. 2015	2	2	2	6	 Justification of sample size unsatisfactory No details of non-responders Non-validated but described method of khat usage data collection Uses self-report
Soboka et al. 2015	3	2	2	7	 All eligible participants invited to participate Limited description of non-responders (gender only) Non-validated but described method of khat usage data collection Uses self-report
Zenebe et al. 2015	3	2	3	8	 No details of non-responders Non-validated but described method of khat usage data collection Medical records used
El-Setouhy et al. 2016	4	2	2	8	Volunteer sample; no non-respondersUses self-report
Hersi et al. 2017	3	2	2	7	 No details of non-responders Non-validated but described method of khat usage data

					collection - Uses self-report	
Hunduma et al. 2017	3	2	2	7	 No details of non-responders Non-validated but described method of khat usage data collection Uses self-report 	
Kerebih et al. 2017	3	2	2	7	 No details of non-responders Non-validated but described method of khat usage data collection Uses self-report 	
Mossie et al. 2016	3	2	2	7	 No details of non-responders Non-validated but described method of khat usage data collection Uses self-report 	
Soboka et al. 2017	2	2	2	6	 Invited all eligible participants Does not discuss whether sample size is large enough for conclusions to be drawn No details of non-responders Non-validated but described method of khat usage data collection Unclear if all variables are self-reported 	
Tariku et al. 2017	3	2	2	7	 No details of non-responders Non-validated but described method of khat usage data collection Uses self report 	
Wondemagegn et al. 2017	3	1	3	7	 No details of non-responders Non-validated but described method of khat usage data collection 	

					- Only one community studied but no other controlled variables	
Yeshaw and Mossie 2017	2	2	2	6	 Sample size not justified No details of non-responders Non-validated but described method of khat usage data collection Uses self-report 	
Bedaso et al. 2018	3	2	2	8	 100% response rate Limited description of khat usage data collection Uses self-report	
Adraro et al. 2019	3	2	2	7	 No details of non-responders Non-validated but described method of khat usage data collection Uses self-report 	
Ongeri et al. 2019	2	2	2	6	 No details of non-responders No description of what quantifies a 'current khat user' Uses self-report 	
Atnafie et al. 2020	3	2	2	7	 No details of non-responders Non-validated but described method of khat usage data collection Uses self-report 	
Hajure et al. 2020	3	2	2	7	 No details of non-responders Non-validated but described method of khat usage data collection Uses self-report 	
Hambisa et al. 2020	3	2	2	7	- No details of non-responders	

					 Non-validated but described method of khat usage data collection Uses self-report 	
Kelemu et al. 2020	3	2	2	7	 No details of non-responders Non-validated but described method of khat usage data collection Uses self-report 	
Mekuriaw et al. 2020	3	2	2	7	 No details of non-responders Non-validated but described method of khat usage data collection Uses self-report 	
Yitayih et al. 2020	4	2	2	8	 Provides reasons for non-responders but not characteristics Uses DAST-10 for khat abuse Uses self-report 	
Haile and Sahile 2021	3	2	2	7	 - 100% response rate - No description of what quantifies a 'current khat user' - Uses self-report 	
Hambisa et al. 2021	2	2	2	6	 Providers reasons for non-responders but not characteristics No description of what quantifies a 'current khat user' Uses self-report 	
Melaku et al. 2021	3	2	2	7	 No details of non-responders Non-validated but described method of khat usage data collection Uses self-report 	

Supplementary Material 4: Sensitivity Analysis

Study Excluded	Odds Ratio	95% Cls	l ² Value (%)	P-Value			
Depression							
Atnafie et al. 2020	2.28	1.81-2.87	91	<0.00001			
Bedaso et al. 2018	2.21	1.75-2.79	92	<0.00001			
Deyessa et al. 2008	2.23	1.76-2.82	92	<0.00001			
El-Setouhy et al. 2016	2.22	1.76-2.80	92	<0.00001			
Haile and Sahile 2021	2.14	1.71-2.69	91	<0.00001			
Hambisa et al 2020	2.24	1.77-2.84	92	<0.00001			
Melaku et al. 2021	2.22	1.76-2.81	92	<0.00001			
Mossie et al. 2016	2.17	1.73-2.73	91	<0.00001			
Numan 2003	2.27	1.80-2.87	91	<0.00001			
Wondemagegn et al. 2017	2.11	1.69-2.64	91	<0.00001			
Yeshaw and Mossie 2017	2.19	1.74-2.76	92	<0.00001			
Zenebe et al. 2015	2.28	1.81-2.87	91	<0.00001			
Anxiety	-		·	-			
Atnafie et al. 2020	2.22	1.75-2.80	92	<0.00001			
El-Setouhy et al. 2016	2.21	1.75-2.79	92	<0.00001			
Melaku et al. 2021	2.22	1.76-2.81	92	<0.00001			
Numan 2003	2.29	1.83-2.86	91	<0.00001			
Numan 2003	2.26	1.79-2.86	92	<0.00001			
Numan 2003	2.27	1.80-2.87	91	<0.00001			
Wondemagegn et al. 2017	2.18	1.73-2.74	91	<0.00001			
Yeshaw and Mossie 2017	2.20	1.75-2.78	92	<0.00001			
Psychological Distress							
Adraro et al. 2019	2.16	1.72-2.71	91	<0.00001			

Atnafie et al. 2020	2.27	1.80-2.87	92	<0.00001
Belew et al. 2000	2.15	1.72-2.69	91	<0.00001
Dachew et al. 2015	2.23	1.76-2.82	92	<0.00001
Damena et al. 2011	2.26	1.78-2.85	92	<0.00001
Dessie et al. 2013	2.21	1.75-2.79	92	<0.00001
Hajure et al. 2020	2.17	1.72-2.73	92	<0.00001
Hambisa et al. 2021	2.19	1.74-2.76	92	<0.00001
Hersi et al. 2017	2.22	1.75-2.80	92	<0.00001
Kelemu et al. 2020	2.23	1.77-2.82	92	<0.00001
Kerebih et al. 2017	2.19	1.74-2.76	92	<0.00001
Mekuriaw et al. 2020	2.19	1.74-2.76	92	<0.00001
Melaku et al. 2021	2.23	1.76-2.81	92	<0.00001
Soboka et al. 2015	2.23	1.77-2.82	92	<0.00001
Soboka et al. 2017	2.24	1.78-2.83	92	<0.00001
Tariku et al. 2017	2.25	1.78-2.84	92	<0.00001
Yeshaw and Mossie et al. 2017	2.21	1.75-2.79	92	<0.00001
Psychotic symptoms/disorders			·	·
Numan 2003	2.26	1.78-2.86	92	<0.00001
Numan 2003	2.27	1.80-2.87	91	<0.00001
Odenwald et al. 2009	2.27	1.80-2.87	91	<0.00001
Ongeri et al. 2019	2.25	1.78-2.85	92	<0.00001
Tulloch et al. 2012	2.14	1.70-2.68	91	<0.00001
Widmann et al. 2014	2.20	1.75-2.77	92	<0.00001
Zenebe et al. 2015	2.23	1.76-2.82	92	<0.00001
Psychopathy		•		
Yitayih et al. 2020	2.18	1.73-2.74	92	<0.00001
Unspecified psychiatric symptoms	/disorders			

Ahmed and Emad 1998	2.24	1.78-2.83	92	<0.00001
Fedaku et al. 2014	2.21	1.75-2.79	92	<0.00001
Hunduma et al. 2017	2.22	1.76-2.81	92	<0.00001
Odenwald et al. 2005	2.23	1.76-2.82	92	<0.00001
Yitayih et al. 2020	2.24	1.77-2.82	92	<0.00001